Assessment	O
of	O
automated	O
analysis	O
of	O
portable	O
oximetry	O
as	O
a	O
screening	O
test	O
for	O
moderate	O
-	O
to	O
-	O
severe	O
sleep	B-DS
apnea	I-DS
in	O
patients	O
with	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Background	O

The	O
coexistence	O
of	O
obstructive	B-DS
sleep	I-DS
apnea	I-DS
syndrome	I-DS
(	O
OSAS	B-DS
)	O
and	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
(	O
COPD	B-DS
)	O
leads	O
to	O
increased	O
morbidity	O
and	O
mortality	O
.	O

The	O
development	O
of	O
home	O
-	O
based	O
screening	O
tests	O
is	O
essential	O
to	O
expedite	O
diagnosis	O
.	O

Nevertheless	O
,	O
there	O
is	O
still	O
very	O
limited	O
evidence	O
on	O
the	O
effectiveness	O
of	O
portable	O
monitoring	O
to	O
diagnose	O
OSAS	B-DS
in	O
patients	O
with	O
pulmonary	O
comorbidities	O
.	O

Objective	O

To	O
assess	O
the	O
influence	O
of	O
suffering	O
from	O
COPD	B-DS
in	O
the	O
performance	O
of	O
an	O
oximetry	O
-	O
based	O
screening	O
test	O
for	O
moderate	O
-	O
to	O
-	O
severe	O
OSAS	B-DS
,	O
both	O
in	O
the	O
hospital	O
and	O
at	O
home	O
.	O

Methods	O

A	O
total	O
of	O
407	O
patients	O
showing	O
moderate	O
-	O
to	O
-	O
high	O
clinical	O
suspicion	O
of	O
OSAS	B-DS
were	O
involved	O
in	O
the	O
study	O
.	O

All	O
subjects	O
underwent	O
(	O
i	O
)	O
supervised	O
portable	O
oximetry	O
simultaneously	O
to	O
in	O
-	O
hospital	O
polysomnography	O
(	O
PSG	O
)	O
and	O
(	O
ii	O
)	O
unsupervised	O
portable	O
oximetry	O
at	O
home	O
.	O

A	O
regression	O
-	O
based	O
multilayer	O
perceptron	O
(	O
MLP	O
)	O
artificial	O
neural	O
network	O
(	O
ANN	O
)	O
was	O
trained	O
to	O
estimate	O
the	O
apnea	O
-	O
hypopnea	O
index	O
(	O
AHI	O
)	O
from	O
portable	O
oximetry	O
recordings	O
.	O

Two	O
independent	O
validation	O
datasets	O
were	O
analyzed	O
:	O
COPD	B-DS
versus	O
non	O
-	O
COPD	B-DS
.	O

Results	O

The	O
portable	O
oximetry	O
-	O
based	O
MLP	O
ANN	O
reached	O
similar	O
intra	O
-	O
class	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
values	O
between	O
the	O
estimated	O
AHI	O
and	O
the	O
actual	O
AHI	O
for	O
the	O
non	O
-	O
COPD	B-DS
and	O
the	O
COPD	B-DS
groups	O
either	O
in	O
the	O
hospital	O
(	O
non	O
-	O
COPD	B-DS
:	O
0	O
.	O
937	O
,	O
0	O
.	O
909	O
–	O
0	O
.	O
956	O
CI95	O
%;	O
COPD	B-DS
:	O
0	O
.	O
936	O
,	O
0	O
.	O
899	O
–	O
0	O
.	O
960	O
CI95	O
%)	O
and	O
at	O
home	O
(	O
non	O
-	O
COPD	B-DS
:	O
0	O
.	O
731	O
,	O
0	O
.	O
631	O
–	O
0	O
.	O
808	O
CI95	O
%;	O
COPD	B-DS
:	O
0	O
.	O
788	O
,	O
0	O
.	O
678	O
–	O
0	O
.	O
864	O
CI95	O
%).	O

Regarding	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
characteristics	O
curve	O
(	O
AUC	O
),	O
no	O
statistically	O
significant	O
differences	O
(	O
p	O
>	O
0	O
.	O
01	O
)	O
between	O
COPD	B-DS
and	O
non	O
-	O
COPD	B-DS
groups	O
were	O
found	O
in	O
both	O
settings	O
,	O
particularly	O
for	O
severe	O
OSAS	B-DS
(	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
):	O
0	O
.	O
97	O
(	O
0	O
.	O
92	O
–	O
0	O
.	O
99	O
CI95	O
%)	O
non	O
-	O
COPD	B-DS
vs	O
.	O
0	O
.	O
98	O
(	O
0	O
.	O
92	O
–	O
1	O
.	O
0	O
CI95	O
%)	O
COPD	B-DS
in	O
the	O
hospital	O
,	O
and	O
0	O
.	O
87	O
(	O
0	O
.	O
79	O
–	O
0	O
.	O
92	O
CI95	O
%)	O
non	O
-	O
COPD	B-DS
vs	O
.	O
0	O
.	O
86	O
(	O
0	O
.	O
75	O
–	O
0	O
.	O
93	O
CI95	O
%)	O
COPD	B-DS
at	O
home	O
.	O

Conclusion	O

The	O
agreement	O
and	O
the	O
diagnostic	O
performance	O
of	O
the	O
estimated	O
AHI	O
from	O
automated	O
analysis	O
of	O
portable	O
oximetry	O
were	O
similar	O
regardless	O
of	O
the	O
presence	O
of	O
COPD	B-DS
both	O
in	O
-	O
lab	O
and	O
at	O
-	O
home	O
.	O

Particularly	O
,	O
portable	O
oximetry	O
could	O
be	O
used	O
as	O
an	O
abbreviated	O
screening	O
test	O
for	O
moderate	O
-	O
to	O
-	O
severe	O
OSAS	B-DS
in	O
patients	O
with	O
COPD	B-DS
.	O

Introduction	O

Obstructive	B-DS
sleep	I-DS
apnea	I-DS
syndrome	I-DS
(	O
OSAS	B-DS
)	O
patients	O
suffer	O
from	O
recurrent	O
episodes	O
of	O
airflow	O
limitation	O
due	O
to	O
intermittent	O
complete	O
or	O
partial	O
collapse	O
of	O
the	O
upper	O
airway	O
while	O
sleeping	O
,	O
leading	O
to	O
non	O
-	O
restful	O
sleep	O
and	O
diminished	O
quality	O
of	O
life	O
[	O
1	O
,	O
2	O
].	O

The	O
burden	O
of	O
OSAS	B-DS
is	O
continuously	O
increasing	O
mainly	O
due	O
to	O
the	O
drawbacks	O
of	O
the	O
standard	O
diagnostic	O
methodology	O
,	O
i	O
.	O
e	O
.	O
in	O
-	O
hospital	O
polysomnography	O
(	O
PSG	O
).	O

While	O
being	O
effective	O
,	O
the	O
availability	O
and	O
accessibility	O
of	O
PSG	O
is	O
very	O
limited	O
and	O
it	O
is	O
considered	O
labor	O
-	O
intensive	O
and	O
expensive	O
[	O
3	O
–	O
5	O
].	O

In	O
order	O
to	O
overcome	O
these	O
limitations	O
,	O
several	O
abbreviated	O
tests	O
for	O
OSAS	B-DS
detection	O
have	O
been	O
proposed	O
during	O
the	O
last	O
years	O
.	O

The	O
use	O
of	O
portable	O
monitors	O
at	O
home	O
focused	O
the	O
attention	O
of	O
many	O
researchers	O
due	O
to	O
their	O
readiness	O
,	O
simplicity	O
,	O
efficiency	O
,	O
and	O
lower	O
cost	O
[	O
4	O
,	O
6	O
–	O
10	O
].	O

Nevertheless	O
,	O
most	O
researchers	O
exclude	O
patients	O
with	O
significant	O
cardiovascular	O
and	O
pulmonary	O
comorbidities	O
from	O
the	O
population	O
under	O
study	O
,	O
which	O
is	O
an	O
important	O
limitation	O
in	O
order	O
to	O
generalize	O
the	O
results	O
.	O

In	O
fact	O
,	O
a	O
recent	O
report	O
of	O
the	O
American	O
Academy	O
of	O
Sleep	O
Medicine	O
(	O
AASM	O
)	O
does	O
not	O
recommend	O
the	O
use	O
of	O
portable	O
monitoring	O
for	O
OSAS	B-DS
screening	O
in	O
such	O
patients	O
because	O
there	O
is	O
still	O
little	O
if	O
any	O
evidence	O
on	O
its	O
effectiveness	O
[	O
11	O
].	O

However	O
,	O
it	O
is	O
known	O
that	O
the	O
prevalence	O
of	O
both	O
cardiovascular	O
and	O
pulmonary	O
comorbidities	O
is	O
high	O
among	O
sleep	B-DS
apnea	I-DS
patients	O
[	O
12	O
,	O
13	O
].	O

Moreover	O
,	O
sleep	B-DS
apnea	I-DS
has	O
been	O
closely	O
related	O
with	O
significant	O
decreased	O
health	O
status	O
and	O
quality	O
of	O
life	O
in	O
the	O
presence	O
of	O
such	O
conditions	O
[	O
12	O
–	O
15	O
].	O

Therefore	O
,	O
there	O
is	O
currently	O
an	O
increasing	O
demand	O
for	O
studies	O
focusing	O
on	O
the	O
assessment	O
of	O
home	O
testing	O
algorithms	O
in	O
patients	O
showing	O
significant	O
comorbidities	O
,	O
especially	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
(	O
COPD	B-DS
)	O
[	O
10	O
,	O
16	O
,	O
17	O
].	O

The	O
coexistence	O
of	O
OSAS	B-DS
and	O
COPD	B-DS
,	O
the	O
so	O
-	O
called	O
overlap	B-DS
syndrome	I-DS
,	O
leads	O
to	O
major	O
social	O
and	O
healthcare	O
-	O
related	O
consequences	O
,	O
mostly	O
in	O
the	O
context	O
of	O
cardiovascular	B-DS
disease	I-DS
[	O
15	O
].	O

Patients	O
showing	O
both	O
conditions	O
simultaneously	O
suffer	O
from	O
more	O
severe	O
oxygen	O
desaturations	O
during	O
sleep	O
than	O
those	O
with	O
either	O
COPD	B-DS
or	O
OSAS	B-DS
alone	O
,	O
as	O
well	O
as	O
worse	O
daytime	O
hypoxemia	O
and	O
hypercapnia	O
[	O
13	O
,	O
15	O
].	O

Therefore	O
,	O
an	O
early	O
diagnosis	O
of	O
OSAS	B-DS
is	O
essential	O
in	O
order	O
to	O
receive	O
an	O
effective	O
treatment	O
and	O
reduce	O
mortality	O
.	O

The	O
revised	O
Global	O
Initiative	O
for	O
Chronic	B-DS
Obstructive	I-DS
Lung	I-DS
Disease	I-DS
(	O
GOLD	O
)	O
guidelines	O
highlight	O
the	O
need	O
for	O
controlling	O
the	O
impact	O
of	O
comorbid	O
conditions	O
[	O
18	O
].	O

Particularly	O
,	O
screening	O
for	O
sleep	B-DS
-	I-DS
related	I-DS
breathing	I-DS
disorders	I-DS
is	O
strongly	O
recommended	O
in	O
COPD	B-DS
patients	O
showing	O
common	O
daytime	O
and	O
/	O
or	O
night	O
symptoms	O
,	O
such	O
as	O
hypersomnolence	B-DS
and	O
frequent	O
sleep	B-DS
arousals	I-DS
[	O
13	O
,	O
15	O
,	O
19	O
].	O

There	O
are	O
very	O
few	O
studies	O
focused	O
on	O
the	O
evaluation	O
of	O
portable	O
oximetry	O
as	O
an	O
abbreviated	O
test	O
for	O
OSAS	B-DS
detection	O
among	O
patients	O
with	O
concomitant	O
COPD	B-DS
[	O
20	O
–	O
22	O
].	O

These	O
studies	O
analyzed	O
small	O
datasets	O
using	O
substantially	O
different	O
methodologies	O
and	O
settings	O
.	O

As	O
a	O
result	O
,	O
contradictory	O
findings	O
are	O
reported	O
.	O

Therefore	O
,	O
further	O
research	O
is	O
needed	O
.	O

Artificial	O
neural	O
networks	O
(	O
ANNs	O
)	O
have	O
demonstrated	O
to	O
be	O
very	O
useful	O
in	O
many	O
applications	O
of	O
medicine	O
and	O
,	O
particularly	O
,	O
in	O
the	O
field	O
of	O
OSAS	B-DS
diagnosis	O
[	O
23	O
–	O
27	O
].	O

In	O
a	O
previous	O
study	O
by	O
our	O
group	O
,	O
we	O
assessed	O
the	O
diagnostic	O
performance	O
of	O
an	O
ANN	O
trained	O
to	O
estimate	O
the	O
apnea	O
-	O
hypopnea	O
index	O
(	O
AHI	O
)	O
of	O
patients	O
suspected	O
of	O
suffering	O
from	O
OSAS	B-DS
using	O
the	O
oximetry	O
signal	O
from	O
a	O
controlled	O
PSG	O
carried	O
out	O
in	O
the	O
hospital	O
[	O
26	O
].	O

In	O
the	O
present	O
study	O
,	O
we	O
propose	O
to	O
use	O
an	O
ANN	O
to	O
estimate	O
the	O
AHI	O
from	O
portable	O
nocturnal	O
oximetry	O
in	O
the	O
presence	O
of	O
COPD	B-DS
.	O

Accordingly	O
,	O
our	O
main	O
goal	O
was	O
to	O
design	O
and	O
exhaustively	O
validate	O
the	O
effectiveness	O
of	O
an	O
ANN	O
-	O
based	O
automated	O
test	O
,	O
assessing	O
how	O
the	O
presence	O
of	O
COPD	B-DS
influences	O
the	O
diagnostic	O
performance	O
of	O
portable	O
oximetry	O
monitoring	O
.	O

Materials	O
and	O
methods	O

Population	O
under	O
study	O

Fig	O
1	O
shows	O
the	O
detailed	O
flowchart	O
of	O
the	O
study	O
.	O

Three	O
patient	O
groups	O
were	O
recruited	O
from	O
June	O
2013	O
to	O
January	O
2015	O
in	O
order	O
to	O
develop	O
our	O
research	O
.	O

Firstly	O
,	O
consecutive	O
patients	O
referred	O
to	O
the	O
sleep	O
unit	O
and	O
regardless	O
of	O
suffering	O
from	O
COPD	B-DS
composed	O
our	O
initial	O
training	O
dataset	O
.	O

Secondly	O
,	O
consecutive	O
patients	O
without	O
COPD	B-DS
referred	O
to	O
the	O
sleep	O
unit	O
composed	O
the	O
non	O
-	O
COPD	B-DS
validation	O
dataset	O
.	O

Finally	O
,	O
consecutive	O
patients	O
referred	O
to	O
the	O
Pneumology	O
outpatient	O
facilities	O
due	O
to	O
COPD	B-DS
and	O
also	O
showing	O
clinical	O
suspicion	O
of	O
OSAS	B-DS
composed	O
the	O
COPD	B-DS
validation	O
dataset	O
.	O

Regarding	O
COPD	B-DS
patients	O
,	O
subjects	O
aged	O
≥	O
35	O
years	O
old	O
,	O
current	O
or	O
ex	O
-	O
smokers	O
with	O
a	O
smoking	O
history	O
of	O
at	O
least	O
10	O
pack	O
/	O
years	O
were	O
considered	O
.	O

At	O
the	O
time	O
of	O
COPD	B-DS
diagnosis	O
,	O
complete	O
pulmonary	O
function	O
evaluation	O
(	O
Master	O
screen	O
PFT	O
,	O
Jaeger	O
)	O
was	O
conducted	O
to	O
confirm	O
the	O
disease	O
,	O
including	O
pre	O
-	O
and	O
post	O
-	O
bronchodilator	O
spirometry	O
,	O
lung	O
volumes	O
,	O
and	O
lung	O
diffusion	O
capacity	O
.	O

According	O
to	O
GOLD	O
[	O
18	O
],	O
patients	O
showing	O
a	O
post	O
-	O
bronchodilator	O
spirometry	O
with	O
forced	O
expired	O
volume	O
in	O
1	O
second	O
to	O
forced	O
vital	O
capacity	O
ratio	O
(	O
FEV1	O
/	O
FVC	O
)	O
<	O
70	O
%	O
were	O
involved	O
in	O
the	O
study	O
.	O

Patients	O
with	O
a	O
previous	O
diagnosis	O
and	O
/	O
or	O
treatment	O
for	O
OSAS	B-DS
,	O
additional	O
sleep	B-DS
disorders	I-DS
,	O
and	O
severe	O
cardiovascular	B-DS
diseases	I-DS
were	O
excluded	O
.	O

Patient	O
recruitment	O
flowchart	O
.	O

PSG	O
:	O
polysomnography	O
;	O
TST	O
:	O
total	O
sleep	O
time	O
.	O

The	O
Ethics	O
Committee	O
of	O
the	O
Río	O
Hortega	O
University	O
Hospital	O
approved	O
the	O
study	O
(	O
approval	O
number	O
:	O
CEIC	O
7	O
/	O
13	O
),	O
which	O
was	O
conducted	O
according	O
to	O
the	O
principles	O
expressed	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

All	O
patients	O
were	O
informed	O
to	O
participate	O
in	O
the	O
study	O
and	O
signed	O
an	O
informed	O
consent	O
.	O

Data	O
collection	O
protocol	O
and	O
sleep	O
studies	O

All	O
subjects	O
underwent	O
two	O
sleep	O
studies	O
during	O
consecutive	O
nights	O
:	O
(	O
i	O
)	O
supervised	O
portable	O
oximetry	O
simultaneously	O
to	O
in	O
-	O
hospital	O
PSG	O
and	O
(	O
ii	O
)	O
unsupervised	O
portable	O
oximetry	O
at	O
home	O
.	O

The	O
sequence	O
of	O
the	O
attended	O
/	O
unattended	O
sleep	O
studies	O
was	O
determined	O
randomly	O
.	O

The	O
AHI	O
from	O
in	O
-	O
lab	O
PSG	O
(	O
AHIPSG	O
)	O
was	O
used	O
to	O
confirm	O
OSAS	B-DS
.	O

In	O
addition	O
,	O
two	O
different	O
estimations	O
of	O
the	O
AHI	O
were	O
computed	O
from	O
portable	O
oximetry	O
using	O
the	O
proposed	O
ANN	O
:	O
(	O
i	O
)	O
estimated	O
AHI	O
from	O
supervised	O
oximetry	O
in	O
the	O
sleep	O
laboratory	O
(	O
AHIOX	O
-	O
LAB	O
)	O
and	O
(	O
ii	O
)	O
estimated	O
AHI	O
from	O
unattended	O
oximetry	O
at	O
home	O
(	O
AHIOX	O
-	O
HOME	O
).	O

Standard	O
in	O
-	O
lab	O
PSG	O
was	O
carried	O
out	O
using	O
a	O
polysomnograph	O
E	O
-	O
series	O
by	O
Compumedics	O
(	O
Compumedics	O
Limited	O
,	O
Victoria	O
,	O
Australia	O
).	O

Electroencephalogram	O
(	O
F3	O
-	O
A2	O
,	O
F4	O
-	O
A1	O
,	O
C3	O
-	O
A2	O
,	O
C4	O
-	O
A1	O
,	O
Cz	O
-	O
A2	O
,	O
O1	O
-	O
A2	O
,	O
O2	O
-	O
A1	O
),	O
electrooculogram	O
(	O
right	O
and	O
left	O
),	O
electromyogram	O
(	O
chin	O
and	O
both	O
tibias	O
),	O
electrocardiogram	O
,	O
respiratory	O
effort	O
(	O
chest	O
and	O
abdominal	O
),	O
respiration	O
(	O
thermistor	O
and	O
nasal	O
pressure	O
),	O
oximetry	O
(	O
SpO2	O
and	O
pulse	O
rate	O
),	O
body	O
position	O
,	O
snoring	O
sounds	O
,	O
and	O
video	O
were	O
recorded	O
and	O
stored	O
for	O
offline	O
inspection	O
by	O
a	O
single	O
trained	O
specialist	O
.	O

The	O
AASM	O
rules	O
were	O
used	O
to	O
score	O
sleep	O
studies	O
and	O
derive	O
the	O
AHI	O
from	O
each	O
PSG	O
[	O
28	O
].	O

All	O
PSGs	O
with	O
a	O
total	O
sleep	O
time	O
(	O
TST	O
)	O
<	O
3	O
h	O
due	O
to	O
significant	O
signal	O
loss	O
(	O
artifacts	O
),	O
voluntary	O
termination	O
of	O
the	O
study	O
by	O
the	O
patient	O
,	O
or	O
insufficient	O
data	O
to	O
assess	O
sleep	O
(	O
low	O
sleep	O
efficiency	O
and	O
/	O
or	O
no	O
REM	O
sleep	O
),	O
were	O
withdrawn	O
from	O
the	O
study	O
[	O
29	O
].	O

The	O
Nonin	O
WristOx2	O
3150	O
(	O
Nonin	O
Medical	O
,	O
Inc	O
.,	O
Plymouth	O
,	O
MI	O
,	O
USA	O
)	O
was	O
used	O
to	O
perform	O
portable	O
oximetry	O
both	O
in	O
the	O
hospital	O
facilities	O
and	O
at	O
patients	O
’	O
home	O
.	O

The	O
SpO2	O
signal	O
were	O
recorded	O
using	O
a	O
finger	O
probe	O
at	O
a	O
sampling	O
rate	O
of	O
1	O
sample	O
per	O
second	O
(	O
1	O
Hz	O
).	O

Both	O
oximetry	O
probes	O
,	O
the	O
one	O
corresponding	O
to	O
the	O
PSG	O
and	O
that	O
corresponding	O
to	O
the	O
portable	O
device	O
,	O
were	O
placed	O
on	O
consecutive	O
fingers	O
of	O
the	O
same	O
hand	O
.	O

Previously	O
to	O
the	O
unsupervised	O
recording	O
at	O
home	O
,	O
all	O
participants	O
received	O
both	O
verbal	O
and	O
written	O
instructions	O
on	O
how	O
to	O
use	O
the	O
oximeter	O
.	O

All	O
portable	O
SpO2	O
recordings	O
with	O
a	O
total	O
recording	O
time	O
(	O
TRT	O
)	O
<	O
4	O
h	O
due	O
to	O
significant	O
signal	O
loss	O
(	O
artifacts	O
),	O
premature	O
battery	O
depletion	O
,	O
or	O
voluntary	O
termination	O
of	O
the	O
recording	O
by	O
the	O
patient	O
,	O
were	O
discarded	O
[	O
30	O
].	O

Additionally	O
,	O
patients	O
who	O
did	O
not	O
complete	O
both	O
in	O
-	O
hospital	O
and	O
at	O
-	O
home	O
studies	O
were	O
also	O
withdrawn	O
from	O
the	O
study	O
.	O

Automated	O
analysis	O
of	O
SpO2	O
from	O
oximetry	O

Pre	O
-	O
processing	O

SpO2	O
recordings	O
were	O
downloaded	O
from	O
the	O
portable	O
oximeter	O
and	O
processed	O
offline	O
.	O

Each	O
recording	O
was	O
scanned	O
and	O
all	O
zero	O
samples	O
and	O
transient	O
deeps	O
due	O
to	O
patient	O
’	O
s	O
movements	O
were	O
removed	O
.	O

Additionally	O
,	O
all	O
changes	O
between	O
consecutive	O
samples	O
greater	O
than	O
or	O
equal	O
to	O
4	O
%/	O
s	O
as	O
well	O
as	O
saturation	O
samples	O
below	O
20	O
%	O
were	O
considered	O
artifacts	O
and	O
removed	O
from	O
the	O
signal	O
[	O
31	O
].	O

When	O
large	O
segments	O
of	O
consecutive	O
artifacts	O
were	O
removed	O
,	O
the	O
remaining	O
valid	O
sections	O
were	O
linked	O
.	O

Linear	O
interpolation	O
was	O
applied	O
if	O
the	O
difference	O
between	O
concatenated	O
samples	O
was	O
≥	O
4	O
%/	O
s	O
in	O
order	O
to	O
avoid	O
the	O
inclusion	O
of	O
non	O
-	O
natural	O
changes	O
in	O
the	O
SpO2	O
time	O
series	O
.	O

Feature	O
extraction	O

Every	O
overnight	O
oximetric	O
profile	O
was	O
characterized	O
using	O
an	O
initial	O
set	O
of	O
features	O
from	O
complementary	O
approaches	O
(	O
time	O
vs	O
.	O
frequency	O
and	O
linear	O
vs	O
.	O

nonlinear	O
),	O
which	O
has	O
demonstrated	O
to	O
be	O
very	O
useful	O
in	O
the	O
context	O
of	O
automated	O
OSAS	B-DS
diagnosis	O
[	O
26	O
,	O
32	O
–	O
34	O
].	O

A	O
total	O
of	O
16	O
variables	O
arranged	O
into	O
4	O
feature	O
subsets	O
were	O
computed	O
:	O
time	O
-	O
domain	O
statistics	O
,	O
frequency	O
-	O
domain	O
statistics	O
,	O
conventional	O
spectral	O
measures	O
,	O
and	O
nonlinear	O
measures	O
.	O

Statistics	O
and	O
nonlinear	O
methods	O
in	O
the	O
time	O
domain	O
were	O
applied	O
to	O
non	O
-	O
overlapping	O
512	O
-	O
sample	O
length	O
segments	O
.	O

Statistics	O
and	O
conventional	O
measures	O
in	O
the	O
frequency	O
domain	O
were	O
derived	O
from	O
the	O
power	O
spectral	O
density	O
(	O
PSD	O
)	O
function	O
.	O

The	O
widely	O
applied	O
Welch	O
’	O
s	O
method	O
(	O
512	O
-	O
sample	O
Hanning	O
window	O
,	O
50	O
%	O
overlapping	O
,	O
1024	O
-	O
sample	O
fast	O
Fourier	O
transform	O
)	O
were	O
used	O
to	O
estimate	O
the	O
spectral	O
content	O
of	O
each	O
recording	O
[	O
35	O
].	O

Time	O
-	O
domain	O
statistics	O
.	O
The	O
position	O
(	O
central	O
tendency	O
)	O
and	O
shape	O
(	O
width	O
,	O
asymmetry	O
,	O
and	O
peakedness	O
)	O
of	O
the	O
normalized	O
data	O
histogram	O
of	O
saturation	O
amplitudes	O
from	O
each	O
oximetric	O
time	O
series	O
were	O
parameterized	O
by	O
means	O
of	O
the	O
1st	O
-	O
to	O
4th	O
-	O
order	O
statistical	O
moments	O
[	O
36	O
],	O
i	O
.	O
e	O
.,	O
mean	O
(	O
M1t	O
),	O
variance	O
(	O
M2t	O
),	O
skewness	O
(	O
M3t	O
),	O
and	O
kurtosis	O
(	O
M4t	O
).	O

Frequency	O
-	O
domain	O
statistics	O
.	O
Similarly	O
,	O
the	O
data	O
histogram	O
of	O
amplitudes	O
from	O
each	O
normalized	O
PSD	O
function	O
was	O
characterized	O
using	O
the	O
1st	O
-	O
to	O
4th	O
-	O
order	O
statistical	O
moments	O
,	O
i	O
.	O
e	O
.,	O
mean	O
(	O
M1f	O
),	O
variance	O
(	O
M2f	O
),	O
skewness	O
(	O
M3f	O
),	O
and	O
kurtosis	O
(	O
M4f	O
)	O
in	O
the	O
frequency	O
domain	O
.	O

In	O
addition	O
,	O
the	O
median	O
frequency	O
(	O
MF	O
)	O
and	O
the	O
spectral	O
entropy	O
(	O
SE	O
)	O
[	O
37	O
]	O
of	O
each	O
PSD	O
were	O
also	O
computed	O
to	O
further	O
characterize	O
the	O
power	O
distribution	O
of	O
the	O
spectrum	O
.	O

Conventional	O
spectral	O
measures	O
.	O
Common	O
amplitude	O
-	O
and	O
power	O
-	O
based	O
measures	O
were	O
also	O
computed	O
to	O
characterize	O
the	O
severity	O
and	O
recurrence	O
of	O
desaturations	O
.	O

The	O
total	O
signal	O
power	O
(	O
PT	O
)	O
as	O
well	O
as	O
the	O
peak	O
amplitude	O
(	O
PA	O
)	O
and	O
relative	O
power	O
(	O
PR	O
)	O
in	O
the	O
frequency	O
band	O
of	O
interest	O
for	O
adult	O
sleep	B-DS
apnea	I-DS
(	O
0	O
.	O
014	O
–	O
0	O
.	O
033	O
Hz	O
)	O
were	O
obtained	O
[	O
29	O
].	O

Nonlinear	O
measures	O
.	O
Sample	O
entropy	O
(	O
SampEn	O
)	O
[	O
38	O
],	O
central	O
tendency	O
measure	O
(	O
CTM	O
)	O
[	O
39	O
],	O
and	O
Lempel	O
-	O
Ziv	O
complexity	O
(	O
LZC	O
)	O
[	O
40	O
]	O
were	O
applied	O
to	O
quantify	O
the	O
irregularity	O
,	O
variability	O
,	O
and	O
complexity	O
of	O
each	O
SpO2	O
recording	O
,	O
respectively	O
.	O

Feature	O
selection	O

The	O
16	O
features	O
derived	O
from	O
every	O
oximetric	O
recording	O
compose	O
a	O
feature	O
pattern	O
that	O
characterizes	O
the	O
presence	O
of	O
OSAS	B-DS
on	O
each	O
subject	O
.	O

As	O
mentioned	O
,	O
this	O
initial	O
feature	O
set	O
comprises	O
valuable	O
information	O
linked	O
with	O
the	O
disease	O
.	O

Nevertheless	O
,	O
an	O
improved	O
as	O
well	O
as	O
reduced	O
feature	O
subset	O
can	O
be	O
derived	O
by	O
applying	O
a	O
feature	O
selection	O
algorithm	O
.	O

Previous	O
works	O
have	O
shown	O
that	O
dimensionality	O
reduction	O
algorithms	O
enhances	O
the	O
prediction	O
ability	O
of	O
oximetric	O
features	O
in	O
the	O
context	O
of	O
OSAS	B-DS
diagnosis	O
[	O
32	O
–	O
34	O
].	O

In	O
this	O
study	O
,	O
the	O
fast	O
correlation	O
-	O
based	O
filter	O
(	O
FCBF	O
),	O
a	O
filter	O
methodology	O
for	O
feature	O
selection	O
independent	O
of	O
the	O
pattern	O
recognition	O
technique	O
,	O
is	O
applied	O
[	O
41	O
].	O

FCBF	O
has	O
been	O
previously	O
assessed	O
in	O
the	O
context	O
of	O
automated	O
analysis	O
of	O
supervised	O
airflow	O
recordings	O
for	O
OSAS	B-DS
detection	O
[	O
42	O
,	O
43	O
].	O

FCBF	O
identifies	O
automatically	O
the	O
most	O
relevant	O
and	O
non	O
-	O
redundant	O
features	O
in	O
terms	O
of	O
the	O
symmetrical	O
uncertainty	O
(	O
SU	O
)	O
[	O
41	O
].	O

SU	O
is	O
a	O
normalization	O
of	O
the	O
so	O
-	O
called	O
information	O
gain	O
(	O
IG	O
),	O
which	O
is	O
a	O
measure	O
of	O
predictability	O
based	O
on	O
the	O
information	O
shared	O
between	O
variables	O
.	O

Two	O
main	O
variable	O
filtering	O
stages	O
are	O
involved	O
:	O
(	O
i	O
)	O
relevance	O
-	O
and	O
(	O
ii	O
)	O
redundancy	O
-	O
based	O
feature	O
selection	O
.	O

Regarding	O
the	O
relevance	O
analysis	O
,	O
the	O
association	O
between	O
each	O
input	O
feature	O
and	O
the	O
severity	O
of	O
the	O
disease	O
was	O
estimated	O
.	O

To	O
achieve	O
this	O
goal	O
,	O
the	O
SU	O
between	O
each	O
feature	O
(	O
Xi	O
)	O
and	O
the	O
standard	O
AHI	O
from	O
PSG	O
(	O
Y	O
)	O
was	O
computed	O
as	O
follows	O
[	O
41	O
]:	O
SUi	O
(	O
Xi	O
,	O
Y	O
)=	O
2IGi	O
(	O
Xi	O
,	O
Y	O
)	O
H	O
(	O
Xi	O
)+	O
H	O
(	O
Y	O
),	O
i	O
=	O
1	O
,…,	O
p	O
,(	O
1	O
)	O
where	O
H	O
refers	O
to	O
the	O
widely	O
known	O
Shannon	O
’	O
s	O
entropy	O
.	O

According	O
to	O
their	O
degree	O
of	O
relevance	O
,	O
original	O
input	O
features	O
are	O
ranked	O
from	O
the	O
most	O
(	O
higher	O
SUi	O
)	O
to	O
the	O
less	O
(	O
lower	O
SUi	O
)	O
relevant	O
.	O

Then	O
,	O
in	O
order	O
to	O
implement	O
the	O
redundancy	O
analysis	O
,	O
SUi	O
,	O
j	O
is	O
computed	O
between	O
each	O
pair	O
of	O
ranked	O
features	O
starting	O
from	O
the	O
most	O
relevant	O
one	O
(	O
i	O
,	O
j	O
=	O
1	O
,	O
…,	O
p	O
;	O
i	O
>	O
j	O
in	O
the	O
ranking	O
).	O

When	O
SUi	O
,	O
j	O
≥	O
SUi	O
,	O
the	O
feature	O
j	O
is	O
removed	O
due	O
to	O
redundancy	O
.	O

Hence	O
,	O
the	O
final	O
optimum	O
feature	O
subset	O
was	O
composed	O
of	O
the	O
most	O
relevant	O
and	O
non	O
-	O
redundant	O
variables	O
from	O
portable	O
oximetry	O
.	O

Pattern	O
recognition	O

ANNs	O
are	O
composed	O
of	O
multiple	O
interconnected	O
nodes	O
,	O
the	O
so	O
-	O
called	O
neurons	O
,	O
arranged	O
in	O
consecutive	O
levels	O
(	O
layers	O
)	O
leading	O
to	O
a	O
highly	O
parallel	O
structure	O
[	O
44	O
].	O

In	O
the	O
OSAS	B-DS
framework	O
,	O
a	O
regression	O
-	O
based	O
ANN	O
is	O
able	O
to	O
estimate	O
the	O
AHI	O
,	O
which	O
is	O
a	O
continuous	O
scalar	O
positive	O
magnitude	O
.	O

Accordingly	O
,	O
a	O
single	O
output	O
neuron	O
is	O
used	O
to	O
approximate	O
the	O
target	O
AHI	O
and	O
a	O
linear	O
activation	O
function	O
ranging	O
[	O
0	O
,	O
∞)	O
is	O
applied	O
to	O
model	O
the	O
regression	O
problem	O
.	O

Therefore	O
,	O
the	O
output	O
of	O
a	O
regression	O
MLP	O
ANN	O
is	O
given	O
by	O
[	O
45	O
]:	O
y	O
=	O
f	O
(	O
x	O
,	O
w	O
)=∑	O
j	O
=	O
1NH	O
[	O
ωjgt	O
(∑	O
i	O
=	O
1dωijxi	O
+	O
bj	O
)+	O
b	O
],(	O
2	O
)	O
where	O
d	O
is	O
the	O
number	O
of	O
features	O
in	O
the	O
optimum	O
input	O
pattern	O
from	O
the	O
previous	O
feature	O
selection	O
process	O
,	O
NH	O
is	O
the	O
number	O
of	O
neurons	O
in	O
the	O
hidden	O
layer	O
,	O
ωj	O
is	O
the	O
weight	O
connecting	O
the	O
hidden	O
neuron	O
hj	O
and	O
the	O
output	O
,	O
b	O
is	O
a	O
bias	O
term	O
linked	O
with	O
the	O
output	O
of	O
the	O
network	O
,	O
ωij	O
is	O
the	O
weight	O
connecting	O
the	O
feature	O
i	O
from	O
the	O
input	O
pattern	O
vector	O
with	O
the	O
hidden	O
neuron	O
hj	O
,	O
bj	O
is	O
the	O
bias	O
of	O
the	O
neuron	O
hj	O
in	O
the	O
hidden	O
layer	O
,	O
and	O
gt	O
(·)	O
is	O
the	O
activation	O
function	O
of	O
the	O
neurons	O
in	O
the	O
hidden	O
layer	O
.	O

Weights	O
and	O
biases	O
are	O
determined	O
automatically	O
during	O
the	O
iterative	O
learning	O
process	O
according	O
to	O
the	O
maximum	O
likelihood	O
principle	O
[	O
44	O
].	O

In	O
order	O
to	O
avoid	O
overfitting	O
,	O
the	O
widely	O
known	O
weight	O
decay	O
regularization	O
technique	O
was	O
applied	O
[	O
44	O
].	O

Model	O
selection	O
,	O
i	O
.	O
e	O
.,	O
optimization	O
of	O
the	O
user	O
-	O
dependent	O
input	O
parameters	O
(	O
number	O
of	O
hidden	O
neurons	O
and	O
regularization	O
),	O
was	O
accomplished	O
by	O
leave	O
-	O
one	O
-	O
out	O
cross	O
-	O
validation	O
(	O
loo	O
-	O
cv	O
)	O
in	O
the	O
training	O
dataset	O
.	O

The	O
loo	O
-	O
cv	O
procedure	O
was	O
repeated	O
100	O
times	O
to	O
avoid	O
a	O
potential	O
bias	O
linked	O
with	O
the	O
random	O
initialization	O
of	O
weights	O
.	O

The	O
average	O
intra	O
-	O
class	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
between	O
the	O
estimated	O
AHI	O
and	O
the	O
actual	O
AHI	O
from	O
PSG	O
was	O
used	O
as	O
the	O
metric	O
for	O
model	O
selection	O
.	O

Next	O
,	O
the	O
whole	O
training	O
set	O
was	O
used	O
to	O
carry	O
out	O
the	O
learning	O
process	O
.	O

Finally	O
,	O
the	O
trained	O
MLP	O
ANN	O
was	O
further	O
assessed	O
using	O
two	O
independent	O
test	O
datasets	O
composed	O
of	O
unseen	O
patients	O
:	O
the	O
non	O
-	O
COPD	B-DS
group	O
and	O
the	O
COPD	B-DS
group	O
.	O

Statistical	O
analysis	O

The	O
software	O
tools	O
Matlab	O
version	O
R2014a	O
and	O
IBM	O
SPSS	O
version	O
19	O
were	O
used	O
for	O
performing	O
signal	O
processing	O
and	O
statistical	O
analyses	O
,	O
respectively	O
.	O

A	O
descriptive	O
analysis	O
of	O
clinical	O
and	O
polysomnographic	O
variables	O
of	O
the	O
population	O
under	O
study	O
was	O
accomplished	O
by	O
computing	O
the	O
median	O
and	O
interquartile	O
range	O
(	O
IQR	O
).	O

The	O
non	O
-	O
parametric	O
Kruskal	O
-	O
Wallis	O
test	O
was	O
used	O
to	O
search	O
for	O
significant	O
differences	O
among	O
the	O
3	O
groups	O
under	O
study	O
for	O
continuous	O
variables	O
,	O
whereas	O
the	O
Chi2	O
test	O
was	O
used	O
for	O
the	O
categorical	O
ones	O
.	O

A	O
p	O
-	O
value	O
<	O
0	O
.	O
01	O
was	O
considered	O
significant	O
.	O

The	O
ICC	O
was	O
computed	O
to	O
measure	O
quantitatively	O
the	O
agreement	O
between	O
the	O
estimated	O
AHI	O
and	O
the	O
actual	O
AHI	O
from	O
PSG	O
.	O

In	O
addition	O
,	O
Bland	O
-	O
Altman	O
and	O
Mountain	O
plots	O
were	O
used	O
to	O
assess	O
qualitatively	O
the	O
agreement	O
between	O
both	O
indices	O
taking	O
into	O
account	O
the	O
groups	O
(	O
COPD	B-DS
and	O
non	O
-	O
COPD	B-DS
)	O
and	O
the	O
settings	O
(	O
in	O
-	O
hospital	O
and	O
at	O
-	O
home	O
)	O
under	O
study	O
.	O

Regarding	O
diagnostic	O
performance	O
assessment	O
,	O
common	O
cutoffs	O
for	O
moderate	O
(	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
)	O
and	O
severe	O
(	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
)	O
OSAS	B-DS
were	O
studied	O
.	O

The	O
following	O
widely	O
known	O
metrics	O
were	O
computed	O
for	O
each	O
cutoff	O
in	O
the	O
independent	O
test	O
datasets	O
:	O
sensitivity	O
(	O
Se	O
),	O
specificity	O
(	O
Sp	O
),	O
positive	O
predictive	O
value	O
(	O
PPV	O
),	O
negative	O
predictive	O
value	O
(	O
NPV	O
),	O
positive	O
likelihood	O
ratio	O
(	O
LR	O
+),	O
negative	O
likelihood	O
ratio	O
(	O
LR	O
-),	O
and	O
accuracy	O
(	O
Acc	O
).	O

Additionally	O
,	O
the	O
area	O
under	O
the	O
receiving	O
operating	O
characteristics	O
curve	O
(	O
AUC	O
)	O
was	O
computed	O
as	O
overall	O
performance	O
measure	O
independent	O
of	O
a	O
particular	O
cutoff	O
.	O

The	O
95	O
%	O
confidence	O
interval	O
(	O
CI95	O
%)	O
was	O
computed	O
for	O
every	O
metric	O
.	O

The	O
recommendations	O
of	O
the	O
STARD	O
task	O
force	O
for	O
reporting	O
diagnostic	O
performance	O
measures	O
in	O
medical	O
research	O
were	O
taken	O
into	O
account	O
[	O
46	O
].	O

Conventional	O
oxygen	O
desaturation	O
indices	O
(	O
ODIs	O
)	O
of	O
3	O
%	O
(	O
ODI3	O
)	O
and	O
4	O
%	O
(	O
ODI4	O
)	O
were	O
assessed	O
for	O
comparison	O
purposes	O
.	O

Results	O

A	O
total	O
of	O
407	O
eligible	O
patients	O
were	O
involved	O
in	O
the	O
study	O
.	O
Fig	O
1	O
shows	O
a	O
detailed	O
description	O
of	O
the	O
recruitment	O
process	O
.	O

Regarding	O
patients	O
withdrawn	O
from	O
the	O
study	O
,	O
12	O
PSGs	O
(	O
2	O
.	O
95	O
%)	O
were	O
discarded	O
due	O
to	O
insufficient	O
total	O
sleep	O
time	O
(	O
TST	O
<	O
3	O
hours	O
),	O
uncompleted	O
PSG	O
(	O
the	O
patient	O
left	O
the	O
study	O
or	O
did	O
not	O
attend	O
to	O
the	O
sleep	O
unit	O
),	O
or	O
because	O
files	O
were	O
corrupted	O
.	O

Similarly	O
,	O
14	O
portable	O
SpO2	O
recordings	O
(	O
3	O
.	O
44	O
%)	O
were	O
removed	O
due	O
to	O
reasons	O
(	O
either	O
technical	O
or	O
human	B-OG
)	O
linked	O
with	O
portable	O
oximetry	O
:	O
6	O
supervised	O
in	O
-	O
hospital	O
oximetry	O
(	O
1	O
.	O
45	O
%)	O
and	O
8	O
unsupervised	O
at	O
home	O
(	O
1	O
.	O
97	O
%).	O

Finally	O
,	O
193	O
patients	O
with	O
suspicion	O
of	O
suffering	O
from	O
OSAS	B-DS
and	O
regardless	O
of	O
COPD	B-DS
composed	O
the	O
training	O
dataset	O
,	O
whereas	O
110	O
patients	O
composed	O
the	O
non	O
-	O
COPD	B-DS
test	O
set	O
and	O
68	O
patients	O
composed	O
the	O
COPD	B-DS
test	O
group	O
.	O

Anthropometric	O
and	O
clinical	O
characteristics	O
of	O
the	O
population	O
under	O
study	O
are	O
summarized	O
in	O
Table	O
1	O
.	O
Table	O
2	O
shows	O
the	O
polysomnographic	O
variables	O
of	O
every	O
group	O
under	O
study	O
.	O

Significant	O
statistical	O
differences	O
between	O
groups	O
were	O
found	O
for	O
CT90	O
,	O
basal	O
,	O
minimum	O
,	O
and	O
average	O
saturation	O
,	O
whereas	O
no	O
significant	O
differences	O
were	O
identified	O
for	O
the	O
ODI3	O
.	O

Regarding	O
sleep	O
staging	O
and	O
respiratory	O
-	O
related	O
events	O
,	O
no	O
significant	O
statistical	O
differences	O
were	O
found	O
among	O
patient	O
groups	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
patient	O
groups	O
under	O
study	O
.	O

Feature	O

Training	O

Test	O
1	O
:	O
non	O
-	O
COPD	B-DS

Test	O
2	O
:	O
COPD	B-DS

p	O
-	O
value	O

Subjects	O
(	O
n	O
)	O

193	O

110	O

68	O

-	O

Age	O
(	O
years	O
)	O

55	O
.	O
0	O
[	O
18	O
.	O
2	O
]	O

55	O
.	O
0	O
[	O
18	O
.	O
0	O
]	O

64	O
.	O
5	O
[	O
11	O
.	O
0	O
]	O

<	O
0	O
.	O
01	O

Males	O
(	O
n	O
)	O

148	O
(	O
76	O
.	O
7	O
%)	O

76	O
(	O
69	O
.	O
1	O
%)	O

60	O
(	O
88	O
.	O
2	O
%)	O

<	O
0	O
.	O
01	O

BMI	O
(	O
Kg	O
/	O
m2	O
)	O

28	O
.	O
3	O
[	O
6	O
.	O
2	O
]	O

28	O
.	O
6	O
[	O
5	O
.	O
8	O
]	O

29	O
.	O
0	O
[	O
5	O
.	O
4	O
]	O

0	O
.	O
739	O

AHI	O
(	O
events	O
/	O
h	O
)	O

33	O
.	O
6	O
[	O
43	O
.	O
8	O
]	O

33	O
.	O
8	O
[	O
41	O
.	O
1	O
]	O

37	O
.	O
8	O
[	O
45	O
.	O
1	O
]	O

0	O
.	O
609	O

AHI	O
≥	O
5	O
events	O
/	O
h	O
(	O
n	O
)	O

174	O
(	O
90	O
.	O
2	O
%)	O

101	O
(	O
91	O
.	O
8	O
%)	O

67	O
(	O
98	O
.	O
5	O
%)	O

0	O
.	O
085	O

AHI	O
≥	O
15	O
events	O
/	O
h	O
(	O
n	O
)	O

143	O
(	O
74	O
.	O
1	O
%)	O

81	O
(	O
73	O
.	O
6	O
%)	O

52	O
(	O
76	O
.	O
5	O
%)	O

0	O
.	O
907	O

AHI	O
≥	O
30	O
events	O
/	O
h	O
(	O
n	O
)	O

108	O
(	O
56	O
.	O
0	O
%)	O

63	O
(	O
57	O
.	O
3	O
%)	O

39	O
(	O
57	O
.	O
4	O
%)	O

0	O
.	O
966	O

Data	O
are	O
presented	O
as	O
median	O
[	O
interquartile	O
range	O
]	O
for	O
quantitative	O
variables	O
whereas	O
n	O
(%)	O
is	O
used	O
for	O
categorical	O
variables	O
.	O

Non	O
-	O
COPD	B-DS
:	O
test	O
dataset	O
composed	O
of	O
patients	O
without	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
COPD	B-DS
:	O
test	O
dataset	O
composed	O
of	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
patients	O
;	O
BMI	O
:	O
body	O
mass	O
index	O
;	O
AHI	O
:	O
apnea	O
-	O
hypopnea	O
index	O
.	O

Polysomnographic	O
variables	O
of	O
the	O
groups	O
under	O
study	O
:	O
Sleep	O
staging	O
,	O
respiratory	O
related	O
events	O
,	O
and	O
oximetric	O
indexes	O
.	O

Feature	O

Training	O

Test	O
1	O
:	O
non	O
-	O
COPD	B-DS

Test	O
2	O
:	O
COPD	B-DS

p	O
-	O
value	O

Sleep	O
efficiency	O
(%)	O

83	O
.	O
7	O
[	O
16	O
.	O
6	O
]	O

84	O
.	O
9	O
[	O
16	O
.	O
9	O
]	O

77	O
.	O
1	O
[	O
23	O
.	O
5	O
]	O

0	O
.	O
011	O

Stage	O
N1	O
(%)	O

14	O
.	O
4	O
[	O
9	O
.	O
7	O
]	O

12	O
.	O
8	O
[	O
15	O
.	O
2	O
]	O

16	O
.	O
2	O
[	O
14	O
.	O
2	O
]	O

0	O
.	O
076	O

Stage	O
N2	O
(%)	O

32	O
.	O
1	O
[	O
13	O
.	O
4	O
]	O

32	O
.	O
4	O
[	O
14	O
.	O
5	O
]	O

28	O
.	O
6	O
[	O
12	O
.	O
4	O
]	O

0	O
.	O
053	O

Stage	O
N3	O
(%)	O

35	O
.	O
8	O
[	O
17	O
.	O
6	O
]	O

35	O
.	O
2	O
[	O
21	O
.	O
7	O
]	O

39	O
.	O
0	O
[	O
17	O
.	O
8	O
]	O

0	O
.	O
337	O

REM	O
sleep	O
(%)	O

15	O
.	O
4	O
[	O
9	O
.	O
6	O
]	O

14	O
.	O
4	O
[	O
8	O
.	O
9	O
]	O

14	O
.	O
6	O
[	O
9	O
.	O
3	O
]	O

0	O
.	O
665	O

Arousal	O
index	O
(	O
events	O
/	O
h	O
)	O

30	O
.	O
5	O
[	O
22	O
.	O
0	O
]	O

25	O
.	O
8	O
[	O
22	O
.	O
9	O
]	O

30	O
.	O
7	O
[	O
15	O
.	O
6	O
]	O

0	O
.	O
061	O

AHI	O
(	O
events	O
/	O
h	O
)	O

33	O
.	O
6	O
[	O
43	O
.	O
8	O
]	O

33	O
.	O
8	O
[	O
41	O
.	O
1	O
]	O

37	O
.	O
8	O
[	O
45	O
.	O
1	O
]	O

0	O
.	O
609	O

AI	O
(	O
events	O
/	O
h	O
)	O

10	O
.	O
9	O
[	O
30	O
.	O
8	O
]	O

10	O
.	O
6	O
[	O
27	O
.	O
9	O
]	O

9	O
.	O
0	O
[	O
28	O
.	O
1	O
]	O

0	O
.	O
934	O

ODI3	O
(	O
events	O
/	O
h	O
)	O

32	O
.	O
7	O
[	O
41	O
.	O
3	O
]	O

35	O
.	O
5	O
[	O
38	O
.	O
2	O
]	O

38	O
.	O
3	O
[	O
43	O
.	O
1	O
]	O

0	O
.	O
509	O

CT90	O
(%)	O

10	O
.	O
5	O
[	O
25	O
.	O
2	O
]	O

10	O
.	O
1	O
[	O
29	O
.	O
9	O
]	O

46	O
.	O
2	O
[	O
66	O
.	O
0	O
]	O

<<	O
0	O
.	O
01	O

SpO2	O
basal	O

94	O
.	O
0	O
[	O
2	O
.	O
0	O
]	O

94	O
.	O
0	O
[	O
2	O
.	O
0	O
]	O

91	O
.	O
0	O
[	O
3	O
.	O
0	O
]	O

<<	O
0	O
.	O
01	O

SpO2	O
min	O

82	O
.	O
0	O
[	O
13	O
.	O
0	O
]	O

81	O
.	O
0	O
[	O
10	O
.	O
0	O
]	O

78	O
.	O
0	O
[	O
11	O
.	O
0	O
]	O

<	O
0	O
.	O
01	O

SpO2	O
mean	O

93	O
.	O
0	O
[	O
3	O
.	O
0	O
]	O

93	O
.	O
0	O
[	O
3	O
.	O
0	O
]	O

90	O
.	O
0	O
[	O
4	O
.	O
0	O
]	O

<<	O
0	O
.	O
01	O

Data	O
are	O
presented	O
as	O
median	O
[	O
interquartile	O
range	O
].	O

Non	O
-	O
COPD	B-DS
:	O
test	O
dataset	O
composed	O
of	O
patients	O
without	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
COPD	B-DS
:	O
test	O
dataset	O
composed	O
of	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
patients	O
;	O
REM	O
:	O
rapid	O
eye	O
movement	O
sleep	O
;	O
AHI	O
:	O
apnea	O
-	O
hypopnea	O
index	O
;	O
ODI3	O
:	O
oxygen	O
desaturation	O
index	O
of	O
3	O
%	O
in	O
the	O
PSG	O
;	O
CT90	O
:	O
percentage	O
of	O
the	O
total	O
sleep	O
time	O
in	O
the	O
PSG	O
with	O
a	O
saturation	O
below	O
90	O
%;	O
SpO2	O
:	O
blood	O
oxygen	O
saturation	O
;	O
min	O
:	O
minimum	O
value	O
in	O
the	O
overall	O
recording	O
.	O

Table	O
3	O
summarizes	O
the	O
characteristics	O
from	O
spirometry	O
of	O
the	O
COPD	B-DS
group	O
.	O

According	O
to	O
GOLD	O
stages	O
[	O
18	O
],	O
23	O
.	O
5	O
%	O
were	O
categorized	O
as	O
GOLD1	O
,	O
57	O
.	O
4	O
%	O
as	O
GOLD2	O
,	O
17	O
.	O
6	O
%	O
as	O
GOLD3	O
,	O
and	O
1	O
.	O
5	O
%	O
as	O
GOLD4	O
.	O

Common	O
pulmonary	O
functional	O
measures	O
of	O
COPD	B-DS
patients	O
derived	O
from	O
post	O
-	O
bronchodilator	O
spirometry	O
.	O

Measure	O
from	O
post	O
-	O
bronchodilator	O
spirometry	O

Median	O
[	O
IQR	O
]	O

FVC	O
(	O
L	O
)	O

2	O
.	O
9	O
[	O
1	O
.	O
4	O
]	O

FVC	O
(%)	O

81	O
.	O
8	O
[	O
27	O
.	O
4	O
]	O

FEV1	O
(	O
liters	O
)	O

1	O
.	O
7	O
[	O
0	O
.	O
9	O
]	O

FEV1	O
(%)	O

63	O
.	O
7	O
[	O
24	O
.	O
4	O
]	O

FEV1	O
/	O
FVC	O

60	O
.	O
6	O
[	O
14	O
.	O
6	O
]	O

FVC	O
improvement	O

4	O
.	O
0	O
[	O
7	O
.	O
9	O
]	O

FEV1	O
improvement	O

4	O
.	O
0	O
[	O
8	O
.	O
3	O
]	O

Data	O
are	O
presented	O
as	O
median	O
[	O
interquartile	O
range	O
].	O

IQR	O
:	O
interquartile	O
range	O
;	O
FEV1	O
:	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
;	O
FVC	O
:	O
forced	O
vital	O
capacity	O
.	O

ANN	O
design	O
in	O
the	O
training	O
dataset	O

In	O
-	O
hospital	O
supervised	O
setting	O

A	O
total	O
of	O
9	O
features	O
were	O
automatically	O
selected	O
from	O
in	O
-	O
lab	O
attended	O
recordings	O
:	O
M1t	O
,	O
M2t	O
,	O
M3t	O
,	O
M4t	O
,	O
MF	O
,	O
PR	O
,	O
SampEn	O
,	O
CTM	O
,	O
and	O
LZC	O
.	O
Fig	O
2A	O
shows	O
the	O
model	O
selection	O
process	O
for	O
the	O
ANN	O
in	O
the	O
training	O
set	O
using	O
these	O
features	O
.	O

The	O
number	O
of	O
neurons	O
in	O
the	O
hidden	O
layer	O
of	O
the	O
optimum	O
ANN	O
from	O
supervised	O
oximetry	O
was	O
NH	O
=	O
12	O
and	O
the	O
regularization	O
parameter	O
was	O
set	O
to	O
ν	O
=	O
1	O
.	O

The	O
proposed	O
ANN	O
achieved	O
0	O
.	O
96	O
ICC	O
(	O
0	O
.	O
95	O
,	O
0	O
.	O
97	O
CI95	O
%)	O
in	O
the	O
whole	O
training	O
dataset	O
.	O

Optimization	O
(	O
model	O
selection	O
)	O
of	O
the	O
MLP	O
ANN	O
in	O
the	O
training	O
set	O
.	O

(	O
A	O
)	O
In	O
-	O
hospital	O
supervised	O
monitoring	O
.	O

(	O
B	O
)	O
At	O
-	O
home	O
unattended	O
monitoring	O
.	O

ICC	O
:	O
intra	O
-	O
class	O
correlation	O
coefficient	O
;	O
NH	O
:	O
number	O
of	O
neurons	O
in	O
the	O
hidden	O
layer	O
;	O
ν	O
:	O
regularization	O
parameter	O
.	O

At	O
-	O
home	O
unsupervised	O
setting	O

Similarly	O
,	O
a	O
total	O
of	O
8	O
features	O
composed	O
the	O
optimum	O
feature	O
subset	O
from	O
unattended	O
recordings	O
at	O
home	O
:	O
M1t	O
,	O
M3t	O
,	O
M4t	O
,	O
SE	O
,	O
PR	O
,	O
SampEn	O
,	O
CTM	O
,	O
and	O
LZC	O
.	O
Fig	O
2B	O
shows	O
the	O
model	O
selection	O
procedure	O
.	O

The	O
optimum	O
ANN	O
from	O
unsupervised	O
oximetry	O
contained	O
NH	O
=	O
12	O
hidden	O
neurons	O
and	O
the	O
regularization	O
parameters	O
was	O
ν	O
=	O
4	O
.	O

The	O
proposed	O
ANN	O
reached	O
0	O
.	O
80	O
ICC	O
(	O
0	O
.	O
75	O
,	O
0	O
.	O
85	O
CI95	O
%)	O
in	O
the	O
whole	O
training	O
set	O
.	O

Performance	O
assessment	O
in	O
the	O
test	O
datasets	O

Agreement	O
with	O
AHI	O
from	O
PSG	O

Table	O
4	O
shows	O
the	O
ICC	O
values	O
achieved	O
by	O
the	O
proposed	O
oximetry	O
-	O
based	O
ANNs	O
and	O
conventional	O
ODI3	O
and	O
ODI4	O
.	O

Regarding	O
the	O
AHIOX	O
-	O
LAB	O
from	O
portable	O
oximetry	O
in	O
the	O
hospital	O
setting	O
,	O
ICC	O
values	O
were	O
very	O
similar	O
in	O
the	O
non	O
-	O
COPD	B-DS
(	O
0	O
.	O
937	O
,	O
CI95	O
%	O
0	O
.	O
909	O
–	O
0	O
.	O
956	O
)	O
and	O
in	O
the	O
COPD	B-DS
(	O
0	O
.	O
936	O
,	O
CI95	O
%	O
0	O
.	O
899	O
–	O
0	O
.	O
960	O
)	O
groups	O
(	O
S1	O
and	O
S2	O
Tables	O
).	O

In	O
the	O
same	O
way	O
,	O
ICC	O
values	O
corresponding	O
to	O
AHIOX	O
-	O
HOME	O
from	O
at	O
-	O
home	O
recordings	O
were	O
again	O
similar	O
among	O
non	O
-	O
COPD	B-DS
(	O
0	O
.	O
731	O
,	O
CI95	O
%	O
0	O
.	O
631	O
–	O
0	O
.	O
808	O
)	O
and	O
COPD	B-DS
(	O
0	O
.	O
788	O
,	O
CI95	O
%	O
0	O
.	O
678	O
–	O
0	O
.	O
864	O
)	O
patients	O
(	O
S1	O
and	O
S2	O
Tables	O
).	O

It	O
is	O
important	O
to	O
note	O
that	O
the	O
estimated	O
AHIOX	O
-	O
LAB	O
and	O
AHIOX	O
-	O
HOME	O
reached	O
notably	O
higher	O
agreement	O
with	O
the	O
actual	O
AHI	O
from	O
PSG	O
than	O
conventional	O
ODIs	O
in	O
both	O
settings	O
.	O

Agreement	O
between	O
estimated	O
AHI	O
using	O
the	O
proposed	O
ANN	O
and	O
conventional	O
ODIs	O
with	O
actual	O
AHI	O
from	O
PSG	O
for	O
the	O
groups	O
and	O
settings	O
under	O
study	O
.	O

Setting	O

In	O
-	O
laboratory	O

At	O
-	O
home	O

Group	O

non	O
-	O
COPD	B-DS

COPD	B-DS

non	O
-	O
COPD	B-DS

COPD	B-DS

Estimated	O
AHI	O

0	O
.	O
937	O

0	O
.	O
936	O

0	O
.	O
731	O

0	O
.	O
788	O

(	O
0	O
.	O
909	O
,	O
0	O
.	O
956	O
)	O

(	O
0	O
.	O
899	O
,	O
0	O
.	O
960	O
)	O

(	O
0	O
.	O
631	O
,	O
0	O
.	O
808	O
)	O

(	O
0	O
.	O
678	O
,	O
0	O
.	O
864	O
)	O

ODI3	O

0	O
.	O
904	O

0	O
.	O
892	O

0	O
.	O
536	O

0	O
.	O
670	O

(	O
0	O
.	O
634	O
,	O
0	O
.	O
960	O
)	O

(	O
0	O
.	O
664	O
,	O
0	O
.	O
952	O
)	O

(	O
0	O
.	O
100	O
,	O
0	O
.	O
751	O
)	O

(	O
0	O
.	O
126	O
,	O
0	O
.	O
856	O
)	O

ODI4	O

0	O
.	O
745	O

0	O
.	O
693	O

0	O
.	O
403	O

0	O
.	O
518	O

(	O
0	O
,	O
0	O
.	O
911	O
)	O

(	O
0	O
,	O
0	O
.	O
819	O
)	O

(	O
0	O
,	O
0	O
.	O
676	O
)	O

(	O
0	O
,	O
0	O
.	O
788	O
)	O

Data	O
are	O
presented	O
as	O
magnitude	O
and	O
95	O
%	O
confidence	O
interval	O
.	O

non	O
-	O
COPD	B-DS
:	O
test	O
dataset	O
composed	O
of	O
patients	O
without	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
COPD	B-DS
:	O
test	O
dataset	O
composed	O
of	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
patients	O
;	O
AHI	O
:	O
apnea	O
-	O
hypopnea	O
index	O
;	O
ODI3	O
:	O
oxygen	O
desaturation	O
index	O
of	O
3	O
%	O
from	O
portable	O
oximetry	O
;	O
ODI4	O
:	O
oxygen	O
desaturation	O
index	O
of	O
4	O
%	O
from	O
portable	O
oximetry	O
.	O

Fig	O
3A	O
–	O
3D	O
depict	O
the	O
Bland	O
-	O
Altman	O
agreement	O
plots	O
for	O
the	O
estimated	O
AHI	O
and	O
the	O
standard	O
AHI	O
for	O
the	O
groups	O
under	O
study	O
.	O

In	O
the	O
hospital	O
,	O
we	O
can	O
observe	O
in	O
Fig	O
3A	O
and	O
3B	O
that	O
the	O
AHIOX	O
-	O
LAB	O
presented	O
a	O
symmetrical	O
behavior	O
and	O
similar	O
dispersion	O
(	O
limits	O
of	O
agreement	O
)	O
in	O
the	O
non	O
-	O
COPD	B-DS
group	O
(	O
confidence	O
interval	O
=	O
39	O
.	O
12	O
)	O
and	O
in	O
the	O
COPD	B-DS
dataset	O
(	O
confidence	O
interval	O
=	O
39	O
.	O
24	O
).	O

In	O
addition	O
,	O
the	O
AHIOX	O
-	O
LAB	O
showed	O
low	O
bias	O
,	O
i	O
.	O
e	O
.,	O
mean	O
difference	O
with	O
the	O
actual	O
AHI	O
,	O
in	O
both	O
groups	O
(	O
non	O
-	O
COPD	B-DS
:	O
1	O
.	O
30	O
;	O
COPD	B-DS
:	O
1	O
.	O
60	O
).	O

Regarding	O
the	O
data	O
derived	O
from	O
unsupervised	O
recordings	O
at	O
home	O
,	O
the	O
Bland	O
-	O
Altman	O
agreement	O
plots	O
in	O
Fig	O
3C	O
and	O
3D	O
show	O
similar	O
dispersion	O
in	O
both	O
datasets	O
(	O
confidence	O
interval	O
:	O
76	O
.	O
37	O
in	O
non	O
-	O
COPD	B-DS
and	O
72	O
.	O
68	O
in	O
COPD	B-DS
)	O
as	O
well	O
as	O
comparable	O
low	O
bias	O
(	O
averaged	O
mean	O
differences	O
:	O
0	O
.	O
61	O
in	O
non	O
-	O
COPD	B-DS
and	O
0	O
.	O
73	O
in	O
COPD	B-DS
)	O
for	O
the	O
AHIOX	O
-	O
HOME	O
.	O

It	O
is	O
important	O
to	O
highlight	O
that	O
no	O
significant	O
differences	O
were	O
found	O
between	O
non	O
-	O
COPD	B-DS
and	O
COPD	B-DS
groups	O
neither	O
in	O
the	O
hospital	O
(	O
p	O
=	O
0	O
.	O
33	O
)	O
nor	O
at	O
home	O
(	O
p	O
=	O
0	O
.	O
48	O
).	O

Mountain	O
plots	O
depicted	O
in	O
Fig	O
4A	O
and	O
4B	O
confirm	O
these	O
findings	O
.	O

Bland	O
-	O
Altman	O
plots	O
showing	O
agreement	O
between	O
estimated	O
AHI	O
from	O
nocturnal	O
oximetry	O
and	O
actual	O
AHI	O
from	O
PSG	O
.	O

(	O
A	O
)	O
Supervised	O
oximetry	O
in	O
the	O
laboratory	O
for	O
non	O
-	O
COPD	B-DS
subjects	O
.	O

(	O
B	O
)	O
Supervised	O
oximetry	O
in	O
the	O
laboratory	O
for	O
COPD	B-DS
patients	O
.	O

(	O
C	O
)	O
Unattended	O
oximetry	O
at	O
home	O
for	O
non	O
-	O
COPD	B-DS
subjects	O
.	O

(	O
D	O
)	O
Unattended	O
oximetry	O
at	O
home	O
for	O
COPD	B-DS
patients	O
.	O

AHIOX	O
-	O
LAB	O
:	O
apnea	O
-	O
hypopnea	O
index	O
from	O
in	O
-	O
hospital	O
oximetry	O
;	O
PSG	O
:	O
polysomnography	O
;	O
in	O
-	O
LAB	O
:	O
supervised	O
setting	O
in	O
the	O
hospital	O
;	O
non	O
-	O
COPD	B-DS
:	O
patients	O
without	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
COPD	B-DS
:	O
patients	O
with	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
AHIOX	O
-	O
HOME	O
:	O
apnea	O
-	O
hypopnea	O
index	O
from	O
at	O
-	O
home	O
oximetry	O
;	O
at	O
-	O
HOME	O
:	O
supervised	O
setting	O
at	O
home	O
.	O

Mountain	O
plots	O
showing	O
differences	O
between	O
the	O
reference	O
AHI	O
from	O
PSG	O
and	O
the	O
estimated	O
AHI	O
of	O
non	O
-	O
COPD	B-DS
and	O
COPD	B-DS
groups	O
.	O

(	O
A	O
)	O
Supervised	O
portable	O
oximetry	O
in	O
the	O
hospital	O
simultaneous	O
to	O
PSG	O
.	O

(	O
B	O
)	O
Unattended	O
portable	O
oximetry	O
at	O
home	O
in	O
a	O
different	O
night	O
.	O

AHIOX	O
-	O
LAB	O
:	O
apnea	O
-	O
hypopnea	O
index	O
from	O
in	O
-	O
hospital	O
oximetry	O
;	O
PSG	O
:	O
polysomnography	O
;	O
non	O
-	O
COPD	B-DS
:	O
patients	O
without	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
COPD	B-DS
:	O
patients	O
with	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
AHIOX	O
-	O
HOME	O
:	O
apnea	O
-	O
hypopnea	O
index	O
from	O
at	O
-	O
home	O
oximetry	O
.	O

Diagnostic	O
performance	O
as	O
a	O
screening	O
test	O
for	O
OSAS	B-DS

Regarding	O
differences	O
between	O
non	O
-	O
COPD	B-DS
and	O
COPD	B-DS
patients	O
in	O
terms	O
of	O
the	O
effectiveness	O
of	O
the	O
simplified	O
oximetry	O
-	O
based	O
test	O
for	O
OSAS	B-DS
,	O
Fig	O
5	O
shows	O
the	O
ROC	O
curves	O
for	O
both	O
groups	O
in	O
the	O
hospital	O
and	O
in	O
the	O
unsupervised	O
setting	O
at	O
home	O
.	O

Notice	O
that	O
no	O
significant	O
differences	O
were	O
found	O
between	O
the	O
curves	O
of	O
both	O
groups	O
for	O
the	O
cutoffs	O
under	O
study	O
.	O

Receiver	O
operating	O
characteristics	O
curves	O
of	O
the	O
estimated	O
AHI	O
.	O

(	O
A	O
)	O
Supervised	O
portable	O
oximetry	O
in	O
the	O
hospital	O
using	O
a	O
cutoff	O
of	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
.	O

(	O
B	O
)	O
Supervised	O
portable	O
oximetry	O
in	O
the	O
hospital	O
using	O
a	O
cutoff	O
of	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
.	O

(	O
C	O
)	O
Unattended	O
portable	O
oximetry	O
at	O
home	O
using	O
a	O
cutoff	O
of	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
.	O

(	O
D	O
)	O
Unattended	O
portable	O
oximetry	O
at	O
home	O
using	O
a	O
cutoff	O
of	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
.	O

AHI	O
:	O
apnea	O
-	O
hypopnea	O
index	O
from	O
standard	O
PSG	O
;	O
non	O
-	O
COPD	B-DS
:	O
patients	O
without	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
COPD	B-DS
:	O
patients	O
with	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
AUC	O
:	O
area	O
under	O
the	O
ROC	O
curve	O
.	O

Tables	O
5	O
and	O
6	O
summarize	O
the	O
performance	O
assessment	O
of	O
the	O
MLPOX	O
-	O
LAB	O
and	O
conventional	O
ODIs	O
for	O
the	O
groups	O
under	O
study	O
in	O
the	O
hospital	O
setting	O
.	O

For	O
each	O
individual	O
cutoff	O
,	O
the	O
estimated	O
AHIOX	O
-	O
LAB	O
using	O
the	O
proposed	O
MLP	O
ANN	O
reached	O
high	O
similar	O
accuracy	O
both	O
in	O
the	O
non	O
-	O
COPD	B-DS
and	O
the	O
COPD	B-DS
groups	O
(	O
87	O
.	O
3	O
%	O
vs	O
.	O

86	O
.	O
8	O
%,	O
and	O
92	O
.	O
7	O
%	O
vs	O
.	O

91	O
.	O
2	O
%	O
for	O
15	O
and	O
30	O
events	O
/	O
h	O
,	O
respectively	O
).	O

On	O
the	O
other	O
hand	O
,	O
conventional	O
ODIs	O
showed	O
notably	O
higher	O
variability	O
between	O
non	O
-	O
COPD	B-DS
and	O
COPD	B-DS
groups	O
.	O

Diagnostic	O
performance	O
of	O
the	O
proposed	O
MLPOX	O
-	O
LAB	O
and	O
conventional	O
ODIs	O
from	O
in	O
-	O
laboratory	O
portable	O
oximetry	O
(	O
simultaneously	O
to	O
the	O
PSG	O
)	O
in	O
the	O
non	O
-	O
COPD	B-DS
test	O
group	O
.	O

Moderate	O
OSAS	B-DS
(	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
)	O

Se	O
(%)	O

Sp	O
(%)	O

PPV	O
(%)	O

NPV	O
(%)	O

LR	O
+	O

LR	O
-	O

Acc	O
(%)	O

AHIOX	O
-	O
LAB	O

97	O
.	O
5	O

58	O
.	O
6	O

86	O
.	O
8	O

89	O
.	O
5	O

2	O
.	O
36	O

0	O
.	O
04	O

87	O
.	O
3	O

(	O
91	O
.	O
4	O
–	O
99	O
.	O
7	O
)	O

(	O
38	O
.	O
9	O
–	O
76	O
.	O
5	O
)	O

(	O
78	O
.	O
1	O
–	O
93	O
.	O
0	O
)	O

(	O
66	O
.	O
9	O
–	O
98	O
.	O
7	O
)	O

(	O
1	O
.	O
5	O
–	O
3	O
.	O
6	O
)	O

(	O
0	O
.	O
01	O
–	O
0	O
.	O
2	O
)	O

(	O
80	O
.	O
0	O
–	O
92	O
.	O
7	O
)	O

ODI3	O

91	O
.	O
4	O

100	O

100	O

80	O
.	O
6	O

NAa	O

0	O
.	O
09	O

93	O
.	O
6	O

(	O
83	O
.	O
2	O
–	O
99	O
.	O
0	O
)	O

(-)	O

(-)	O

(	O
63	O
.	O
4	O
–	O
97	O
.	O
5	O
)	O

(-)	O

(	O
0	O
.	O
01	O
–	O
0	O
.	O
17	O
)	O

(	O
87	O
.	O
6	O
–	O
99	O
.	O
3	O
)	O

ODI4	O

69	O
.	O
1	O

100	O

100	O

53	O
.	O
7	O

NAa	O

0	O
.	O
31	O

77	O
.	O
3	O

(	O
56	O
.	O
6	O
–	O
81	O
.	O
5	O
)	O

(-)	O

(-)	O

(	O
38	O
.	O
0	O
–	O
69	O
.	O
7	O
)	O

(-)	O

(	O
0	O
.	O
19	O
–	O
0	O
.	O
43	O
)	O

(	O
67	O
.	O
7	O
–	O
86	O
.	O
5	O
)	O

Severe	O
OSAS	B-DS
(	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
)	O

Se	O
(%)	O

Sp	O
(%)	O

PPV	O
(%)	O

NPV	O
(%)	O

LR	O
+	O

LR	O
-	O

Acc	O
(%)	O

AHIOX	O
-	O
LAB	O

95	O
.	O
2	O

89	O
.	O
4	O

92	O
.	O
3	O

93	O
.	O
3	O

8	O
.	O
95	O

0	O
.	O
05	O

92	O
.	O
7	O

(	O
86	O
.	O
7	O
–	O
99	O
.	O
0	O
)	O

(	O
76	O
.	O
9	O
–	O
96	O
.	O
5	O
)	O

(	O
83	O
.	O
0	O
–	O
97	O
.	O
5	O
)	O

(	O
81	O
.	O
7	O
–	O
98	O
.	O
6	O
)	O

(	O
3	O
.	O
9	O
–	O
20	O
.	O
5	O
)	O

(	O
0	O
.	O
02	O
–	O
0	O
.	O
2	O
)	O

(	O
86	O
.	O
4	O
–	O
96	O
.	O
4	O
)	O

ODI3	O

76	O
.	O
2	O

100	O

100	O

75	O
.	O
8	O

NAa	O

0	O
.	O
24	O

86	O
.	O
4	O

(	O
62	O
.	O
5	O
–	O
88	O
.	O
7	O
)	O

(-)	O

(-)	O

(	O
61	O
.	O
7	O
–	O
87	O
.	O
8	O
)	O

(-)	O

(	O
0	O
.	O
11	O
–	O
0	O
.	O
38	O
)	O

(	O
78	O
.	O
2	O
–	O
93	O
.	O
9	O
)	O

ODI4	O

41	O
.	O
3	O

100	O

100	O

56	O
.	O
0	O

NAa	O

0	O
.	O
59	O

66	O
.	O
4	O

(	O
26	O
.	O
4	O
–	O
56	O
.	O
6	O
)	O

(-)	O

(-)	O

(	O
42	O
.	O
8	O
–	O
68	O
.	O
4	O
)	O

(-)	O

(	O
0	O
.	O
43	O
–	O
0	O
.	O
74	O
)	O

(	O
55	O
.	O
2	O
–	O
76	O
.	O
7	O
)	O

Data	O
are	O
presented	O
as	O
magnitude	O
and	O
95	O
%	O
confidence	O
interval	O
.	O

AHI	O
:	O
apnea	O
-	O
hypopnea	O
index	O
;	O
Se	O
:	O
sensitivity	O
;	O
Sp	O
:	O
specificity	O
;	O
PPV	O
:	O
positive	O
predictive	O
value	O
;	O
NPV	O
:	O
negative	O
predictive	O
value	O
;	O
LR	O
+:	O
positive	O
likelihood	O
ratio	O
;	O
LR	O
-:	O
negative	O
likelihood	O
ratio	O
;	O
Acc	O
:	O
accuracy	O
;	O
AHIOX	O
-	O
LAB	O
:	O
estimated	O
AHI	O
from	O
in	O
-	O
laboratory	O
nocturnal	O
oximetry	O
;	O
ODI3	O
:	O
oxygen	O
desaturation	O
index	O
of	O
3	O
%;	O
ODI4	O
:	O
oxygen	O
desaturation	O
index	O
of	O
4	O
%.	O

a	O
NA	O
:	O
if	O
Sp	O
=	O
100	O
%,	O
then	O
LR	O
+	O
is	O
not	O
defined	O
.	O

Diagnostic	O
performance	O
of	O
the	O
proposed	O
MLPOX	O
-	O
LAB	O
and	O
conventional	O
ODIs	O
from	O
in	O
-	O
laboratory	O
portable	O
oximetry	O
(	O
simultaneously	O
to	O
the	O
PSG	O
)	O
in	O
the	O
COPD	B-DS
test	O
group	O
.	O

Moderate	O
OSAS	B-DS
(	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
)	O

Se	O
(%)	O

Sp	O
(%)	O

PPV	O
(%)	O

NPV	O
(%)	O

LR	O
+	O

LR	O
-	O

Acc	O
(%)	O

AHIOX	O
-	O
LAB	O

96	O
.	O
2	O

56	O
.	O
3	O

87	O
.	O
7	O

81	O
.	O
8	O

2	O
.	O
20	O

0	O
.	O
07	O

86	O
.	O
8	O

(	O
86	O
.	O
8	O
–	O
99	O
.	O
5	O
)	O

(	O
29	O
.	O
9	O
–	O
80	O
.	O
2	O
)	O

(	O
76	O
.	O
3	O
–	O
94	O
.	O
9	O
)	O

(	O
48	O
.	O
2	O
–	O
97	O
.	O
7	O
)	O

(	O
1	O
.	O
3	O
–	O
3	O
.	O
8	O
)	O

(	O
0	O
.	O
02	O
–	O
0	O
.	O
3	O
)	O

(	O
76	O
.	O
5	O
–	O
94	O
.	O
1	O
)	O

ODI3	O

88	O
.	O
5	O

87	O
.	O
5	O

95	O
.	O
8	O

70	O
.	O
0	O

7	O
.	O
08	O

0	O
.	O
13	O

88	O
.	O
2	O

(	O
77	O
.	O
5	O
–	O
98	O
.	O
6	O
)	O

(	O
66	O
.	O
7	O
–	O
100	O
)	O

(	O
88	O
.	O
2	O
–	O
100	O
)	O

(	O
43	O
.	O
7	O
–	O
96	O
.	O
3	O
)	O

(	O
2	O
.	O
42	O
–	O
12	O
.	O
13	O
)	O

(	O
0	O
.	O
02	O
–	O
0	O
.	O
27	O
)	O

(	O
79	O
.	O
1	O
–	O
96	O
.	O
1	O
)	O

ODI4	O

73	O
.	O
1	O

100	O

100	O

53	O
.	O
3	O

NAa	O

0	O
.	O
27	O

79	O
.	O
4	O

(	O
58	O
.	O
8	O
–	O
87	O
.	O
2	O
)	O

(-)	O

(-)	O

(	O
30	O
.	O
5	O
–	O
75	O
.	O
3	O
)	O

(-)	O

(	O
0	O
.	O
13	O
–	O
0	O
.	O
41	O
)	O

(	O
68	O
.	O
1	O
–	O
90	O
.	O
4	O
)	O

Severe	O
OSAS	B-DS
(	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
)	O

Se	O
(%)	O

Sp	O
(%)	O

PPV	O
(%)	O

NPV	O
(%)	O

LR	O
+	O

LR	O
-	O

Acc	O
(%)	O

AHIOX	O
-	O
LAB	O

97	O
.	O
4	O

82	O
.	O
8	O

88	O
.	O
4	O

96	O
.	O
0	O

5	O
.	O
65	O

0	O
.	O
03	O

91	O
.	O
2	O

(	O
86	O
.	O
5	O
–	O
99	O
.	O
9	O
)	O

(	O
64	O
.	O
2	O
–	O
94	O
.	O
2	O
)	O

(	O
74	O
.	O
9	O
–	O
96	O
.	O
1	O
)	O

(	O
79	O
.	O
6	O
–	O
99	O
.	O
9	O
)	O

(	O
2	O
.	O
5	O
–	O
12	O
.	O
6	O
)	O

(	O
0	O
.	O
004	O
–	O
0	O
.	O
2	O
)	O

(	O
80	O
.	O
9	O
–	O
95	O
.	O
6	O
)	O

ODI3	O

92	O
.	O
3	O

93	O
.	O
1	O

94	O
.	O
7	O

90	O
.	O
0	O

13	O
.	O
39	O

0	O
.	O
08	O

92	O
.	O
7	O

(	O
81	O
.	O
2	O
–	O
100	O
)	O

(	O
80	O
.	O
8	O
–	O
100	O
)	O

(	O
85	O
.	O
2	O
–	O
100	O
)	O

(	O
75	O
.	O
6	O
–	O
100	O
)	O

(	O
4	O
.	O
50	O
–	O
20	O
.	O
30	O
)	O

(	O
0	O
–	O
0	O
.	O
20	O
)	O

(	O
84	O
.	O
6	O
–	O
99	O
.	O
5	O
)	O

ODI4	O

53	O
.	O
9	O

100	O

100	O

61	O
.	O
7	O

NAa	O

0	O
.	O
46	O

73	O
.	O
5	O

(	O
33	O
.	O
5	O
–	O
74	O
.	O
0	O
)	O

(-)	O

(-)	O

(	O
43	O
.	O
4	O
–	O
79	O
.	O
5	O
)	O

(-)	O

(	O
0	O
.	O
26	O
–	O
0	O
.	O
67	O
)	O

(	O
59	O
.	O
2	O
–	O
86	O
.	O
5	O
)	O

Data	O
are	O
presented	O
as	O
magnitude	O
and	O
95	O
%	O
confidence	O
interval	O
.	O

AHI	O
:	O
apnea	O
-	O
hypopnea	O
index	O
;	O
Se	O
:	O
sensitivity	O
;	O
Sp	O
:	O
specificity	O
;	O
PPV	O
:	O
positive	O
predictive	O
value	O
;	O
NPV	O
:	O
negative	O
predictive	O
value	O
;	O
LR	O
+:	O
positive	O
likelihood	O
ratio	O
;	O
LR	O
-:	O
negative	O
likelihood	O
ratio	O
;	O
Acc	O
:	O
accuracy	O
;	O
AHIOX	O
-	O
LAB	O
:	O
estimated	O
AHI	O
from	O
in	O
-	O
laboratory	O
nocturnal	O
oximetry	O
;	O
ODI3	O
:	O
oxygen	O
desaturation	O
index	O
of	O
3	O
%;	O
ODI4	O
:	O
oxygen	O
desaturation	O
index	O
of	O
4	O
%.	O

a	O
NA	O
:	O
if	O
Sp	O
=	O
100	O
%,	O
then	O
LR	O
+	O
is	O
not	O
defined	O
.	O

Tables	O
7	O
and	O
8	O
summarize	O
the	O
diagnostic	O
assessment	O
of	O
the	O
MLPOX	O
-	O
HOME	O
and	O
conventional	O
ODIs	O
in	O
the	O
unattended	O
setting	O
at	O
home	O
.	O

Regarding	O
the	O
estimated	O
AHI	O
using	O
the	O
proposed	O
MLP	O
ANN	O
,	O
moderate	O
accuracies	O
were	O
achieved	O
in	O
both	O
populations	O
:	O
78	O
.	O
2	O
%	O
vs	O
.	O

75	O
.	O
0	O
%,	O
and	O
76	O
.	O
4	O
%	O
vs	O
.	O

77	O
.	O
9	O
%	O
in	O
non	O
-	O
COPD	B-DS
and	O
COPD	B-DS
groups	O
for	O
cutoffs	O
of	O
15	O
and	O
30	O
events	O
/	O
h	O
,	O
respectively	O
.	O

Imbalance	O
in	O
the	O
sensitivity	O
–	O
specificity	O
pair	O
increased	O
compared	O
to	O
the	O
hospital	O
setting	O
thought	O
remained	O
similar	O
in	O
both	O
patient	O
groups	O
.	O

On	O
the	O
other	O
hand	O
,	O
conventional	O
ODI3	O
and	O
ODI4	O
showed	O
the	O
common	O
higher	O
specificity	O
inherent	O
to	O
oximetry	O
as	O
well	O
as	O
a	O
notably	O
higher	O
variability	O
between	O
patients	O
with	O
and	O
without	O
COPD	B-DS
.	O

Diagnostic	O
performance	O
of	O
the	O
proposed	O
MLPOX	O
-	O
HOME	O
and	O
conventional	O
ODIs	O
from	O
portable	O
oximetry	O
at	O
home	O
(	O
unattended	O
in	O
a	O
different	O
preceding	O
/	O
consecutive	O
night	O
to	O
PSG	O
)	O
in	O
the	O
non	O
-	O
COPD	B-DS
test	O
group	O
.	O

Moderate	O
OSAS	B-DS
(	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
)	O

Se	O
(%)	O

Sp	O
(%)	O

PPV	O
(%)	O

NPV	O
(%)	O

LR	O
+	O

LR	O
-	O

Acc	O
(%)	O

AHIOX	O
-	O
HOME	O

97	O
.	O
5	O

24	O
.	O
1	O

78	O
.	O
2	O

77	O
.	O
8	O

1	O
.	O
29	O

0	O
.	O
10	O

78	O
.	O
2	O

(	O
91	O
.	O
4	O
–	O
99	O
.	O
7	O
)	O

(	O
10	O
.	O
3	O
–	O
43	O
.	O
5	O
)	O

(	O
68	O
.	O
9	O
–	O
85	O
.	O
8	O
)	O

(	O
40	O
.	O
0	O
–	O
97	O
.	O
2	O
)	O

(	O
1	O
.	O
0	O
–	O
1	O
.	O
6	O
)	O

(	O
0	O
.	O
02	O
–	O
0	O
.	O
5	O
)	O

(	O
69	O
.	O
1	O
–	O
84	O
.	O
6	O
)	O

ODI3	O

59	O
.	O
3	O

93	O
.	O
1	O

96	O
.	O
0	O

45	O
.	O
0	O

8	O
.	O
59	O

0	O
.	O
44	O

68	O
.	O
2	O

(	O
46	O
.	O
4	O
–	O
71	O
.	O
9	O
)	O

(	O
80	O
.	O
7	O
–	O
100	O
)	O

(	O
88	O
.	O
3	O
–	O
100	O
)	O

(	O
30	O
.	O
2	O
–	O
60	O
.	O
1	O
)	O

(	O
2	O
.	O
81	O
–	O
13	O
.	O
66	O
)	O

(	O
0	O
.	O
30	O
–	O
0	O
.	O
60	O
)	O

(	O
57	O
.	O
6	O
–	O
78	O
.	O
3	O
)	O

ODI4	O

45	O
.	O
7	O

100	O

100	O

39	O
.	O
7	O

NAa	O

0	O
.	O
54	O

60	O
.	O
0	O

(	O
32	O
.	O
7	O
–	O
58	O
.	O
6	O
)	O

(-)	O

(-)	O

(	O
26	O
.	O
7	O
–	O
52	O
.	O
3	O
)	O

(-)	O

(	O
0	O
.	O
41	O
–	O
0	O
.	O
67	O
)	O

(	O
49	O
.	O
2	O
–	O
70	O
.	O
4	O
)	O

Severe	O
OSAS	B-DS
(	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
)	O

Se	O
(%)	O

Sp	O
(%)	O

PPV	O
(%)	O

NPV	O
(%)	O

LR	O
+	O

LR	O
-	O

Acc	O
(%)	O

AHIOX	O
-	O
HOME	O

81	O
.	O
0	O

70	O
.	O
2	O

78	O
.	O
5	O

73	O
.	O
3	O

2	O
.	O
72	O

0	O
.	O
27	O

76	O
.	O
4	O

(	O
69	O
.	O
1	O
–	O
89	O
.	O
8	O
)	O

(	O
55	O
.	O
1	O
–	O
82	O
.	O
7	O
)	O

(	O
66	O
.	O
5	O
–	O
87	O
.	O
7	O
)	O

(	O
58	O
.	O
1	O
–	O
85	O
.	O
4	O
)	O

(	O
1	O
.	O
7	O
–	O
4	O
.	O
3	O
)	O

(	O
0	O
.	O
2	O
–	O
0	O
.	O
5	O
)	O

(	O
67	O
.	O
3	O
–	O
83	O
.	O
6	O
)	O

ODI3	O

44	O
.	O
4	O

97	O
.	O
9	O

96	O
.	O
6	O

56	O
.	O
8	O

20	O
.	O
89	O

0	O
.	O
57	O

67	O
.	O
3	O

(	O
29	O
.	O
3	O
–	O
59	O
.	O
0	O
)	O

(	O
92	O
.	O
9	O
–	O
100	O
)	O

(	O
86	O
.	O
9	O
–	O
100	O
)	O

(	O
43	O
.	O
5	O
–	O
69	O
.	O
3	O
)	O

(	O
4	O
.	O
84	O
–	O
18	O
.	O
42	O
)	O

(	O
0	O
.	O
42	O
–	O
0	O
.	O
73	O
)	O

(	O
56	O
.	O
3	O
–	O
77	O
.	O
1	O
)	O

ODI4	O

23	O
.	O
8	O

97	O
.	O
9	O

93	O
.	O
8	O

48	O
.	O
9	O

11	O
.	O
19	O

0	O
.	O
78	O

55	O
.	O
5	O

(	O
12	O
.	O
0	O
–	O
36	O
.	O
2	O
)	O

(	O
92	O
.	O
9	O
–	O
100	O
)	O

(	O
76	O
.	O
8	O
–	O
100	O
)	O

(	O
36	O
.	O
6	O
–	O
61	O
.	O
2	O
)	O

(	O
2	O
.	O
12	O
–	O
11	O
.	O
99	O
)	O

(	O
0	O
.	O
65	O
–	O
0	O
.	O
91	O
)	O

(	O
44	O
.	O
4	O
–	O
66	O
.	O
8	O
)	O

Data	O
are	O
presented	O
as	O
magnitude	O
and	O
95	O
%	O
confidence	O
interval	O
.	O

AHI	O
:	O
apnea	O
-	O
hypopnea	O
index	O
;	O
Se	O
:	O
sensitivity	O
;	O
Sp	O
:	O
specificity	O
;	O
PPV	O
:	O
positive	O
predictive	O
value	O
;	O
NPV	O
:	O
negative	O
predictive	O
value	O
;	O
LR	O
+:	O
positive	O
likelihood	O
ratio	O
;	O
LR	O
-:	O
negative	O
likelihood	O
ratio	O
;	O
Acc	O
:	O
accuracy	O
;	O
AHIOX	O
-	O
HOME	O
:	O
estimated	O
AHI	O
from	O
at	O
-	O
home	O
nocturnal	O
oximetry	O
;	O
ODI3	O
:	O
oxygen	O
desaturation	O
index	O
of	O
3	O
%;	O
ODI4	O
:	O
oxygen	O
desaturation	O
index	O
of	O
4	O
%.	O

a	O
NA	O
:	O
if	O
Sp	O
=	O
100	O
%,	O
then	O
LR	O
+	O
is	O
not	O
defined	O
.	O

Diagnostic	O
performance	O
of	O
the	O
proposed	O
MLPOX	O
-	O
HOME	O
and	O
conventional	O
ODIs	O
from	O
portable	O
oximetry	O
at	O
home	O
(	O
unattended	O
in	O
a	O
different	O
preceding	O
/	O
consecutive	O
night	O
to	O
PSG	O
)	O
in	O
the	O
COPD	B-DS
test	O
group	O
.	O

Moderate	O
OSAS	B-DS
(	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
)	O

Se	O
(%)	O

Sp	O
(%)	O

PPV	O
(%)	O

NPV	O
(%)	O

LR	O
+	O

LR	O
-	O

Acc	O
(%)	O

AHIOX	O
-	O
HOME	O

86	O
.	O
5	O

37	O
.	O
5	O

81	O
.	O
8	O

46	O
.	O
2	O

1	O
.	O
39	O

0	O
.	O
36	O

75	O
.	O
0	O

(	O
74	O
.	O
2	O
–	O
94	O
.	O
4	O
)	O

(	O
15	O
.	O
2	O
–	O
64	O
.	O
6	O
)	O

(	O
69	O
.	O
1	O
–	O
90	O
.	O
9	O
)	O

(	O
19	O
.	O
2	O
–	O
74	O
.	O
9	O
)	O

(	O
0	O
.	O
9	O
–	O
2	O
.	O
1	O
)	O

(	O
0	O
.	O
1	O
–	O
0	O
.	O
9	O
)	O

(	O
63	O
.	O
2	O
–	O
83	O
.	O
8	O
)	O

ODI3	O

69	O
.	O
2	O

93	O
.	O
8	O

97	O
.	O
3	O

48	O
.	O
4	O

11	O
.	O
08	O

0	O
.	O
33	O

75	O
.	O
0	O

(	O
54	O
.	O
2	O
–	O
84	O
.	O
5	O
)	O

(	O
76	O
.	O
8	O
–	O
100	O
)	O

(	O
90	O
.	O
4	O
–	O
100	O
)	O

(	O
26	O
.	O
5	O
–	O
70	O
.	O
5	O
)	O

(	O
2	O
.	O
44	O
–	O
11	O
.	O
36	O
)	O

(	O
0	O
.	O
16	O
–	O
0	O
.	O
52	O
)	O

(	O
62	O
.	O
7	O
–	O
87	O
.	O
2	O
)	O

ODI4	O

48	O
.	O
1	O

93	O
.	O
8	O

96	O
.	O
2	O

35	O
.	O
7	O

7	O
.	O
69	O

0	O
.	O
55	O

58	O
.	O
8	O

(	O
31	O
.	O
3	O
–	O
65	O
.	O
9	O
)	O

(	O
76	O
.	O
8	O
–	O
100	O
)	O

(	O
85	O
.	O
6	O
–	O
100	O
)	O

(	O
18	O
.	O
2	O
–	O
54	O
.	O
2	O
)	O

(	O
1	O
.	O
68	O
–	O
7	O
.	O
80	O
)	O

(	O
0	O
.	O
36	O
–	O
0	O
.	O
77	O
)	O

(	O
44	O
.	O
8	O
–	O
73	O
.	O
4	O
)	O

Severe	O
OSAS	B-DS
(	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
)	O

Se	O
(%)	O

Sp	O
(%)	O

PPV	O
(%)	O

NPV	O
(%)	O

LR	O
+	O

LR	O
-	O

Acc	O
(%)	O

AHIOX	O
-	O
HOME	O

84	O
.	O
6	O

69	O
.	O
0	O

78	O
.	O
6	O

76	O
.	O
9	O

2	O
.	O
73	O

0	O
.	O
22	O

77	O
.	O
9	O

(	O
69	O
.	O
5	O
–	O
94	O
.	O
1	O
)	O

(	O
49	O
.	O
2	O
–	O
84	O
.	O
7	O
)	O

(	O
63	O
.	O
2	O
–	O
89	O
.	O
7	O
)	O

(	O
56	O
.	O
4	O
–	O
91	O
.	O
0	O
)	O

(	O
1	O
.	O
6	O
–	O
4	O
.	O
8	O
)	O

(	O
0	O
.	O
1	O
–	O
0	O
.	O
5	O
)	O

(	O
67	O
.	O
0	O
–	O
86	O
.	O
8	O
)	O

ODI3	O

61	O
.	O
5	O

96	O
.	O
6	O

96	O
.	O
0	O

65	O
.	O
1	O

17	O
.	O
85	O

0	O
.	O
40	O

76	O
.	O
5	O

(	O
42	O
.	O
0	O
–	O
80	O
.	O
0	O
)	O

(	O
88	O
.	O
0	O
–	O
100	O
)	O

(	O
84	O
.	O
9	O
–	O
100	O
)	O

(	O
47	O
.	O
2	O
–	O
82	O
.	O
8	O
)	O

(	O
4	O
.	O
15	O
–	O
18	O
.	O
10	O
)	O

(	O
0	O
.	O
21	O
–	O
0	O
.	O
61	O
)	O

(	O
63	O
.	O
9	O
–	O
87	O
.	O
8	O
)	O

ODI4	O

35	O
.	O
9	O

96	O
.	O
6	O

93	O
.	O
3	O

52	O
.	O
8	O

10	O
.	O
41	O

0	O
.	O
66	O

61	O
.	O
8	O

(	O
17	O
.	O
5	O
–	O
55	O
.	O
0	O
)	O

(	O
88	O
.	O
0	O
–	O
100	O
)	O

(	O
76	O
.	O
3	O
–	O
100	O
)	O

(	O
36	O
.	O
6	O
–	O
69	O
.	O
2	O
)	O

(	O
1	O
.	O
99	O
–	O
10	O
.	O
50	O
)	O

(	O
0	O
.	O
46	O
–	O
0	O
.	O
87	O
)	O

(	O
47	O
.	O
4	O
–	O
75	O
.	O
9	O
)	O

Data	O
are	O
presented	O
as	O
magnitude	O
and	O
95	O
%	O
confidence	O
interval	O
.	O

AHI	O
:	O
apnea	O
-	O
hypopnea	O
index	O
;	O
Se	O
:	O
sensitivity	O
;	O
Sp	O
:	O
specificity	O
;	O
PPV	O
:	O
positive	O
predictive	O
value	O
;	O
NPV	O
:	O
negative	O
predictive	O
value	O
;	O
LR	O
+:	O
positive	O
likelihood	O
ratio	O
;	O
LR	O
-:	O
negative	O
likelihood	O
ratio	O
;	O
Acc	O
:	O
accuracy	O
;	O
AHIOX	O
-	O
HOME	O
:	O
estimated	O
AHI	O
from	O
at	O
-	O
home	O
nocturnal	O
oximetry	O
;	O
ODI3	O
:	O
oxygen	O
desaturation	O
index	O
of	O
3	O
%;	O
ODI4	O
:	O
oxygen	O
desaturation	O
index	O
of	O
4	O
%.	O

Discussion	O

In	O
the	O
present	O
study	O
,	O
portable	O
oximetry	O
was	O
assessed	O
as	O
a	O
simplified	O
tool	O
for	O
OSAS	B-DS
diagnosis	O
in	O
COPD	B-DS
patients	O
.	O

In	O
order	O
to	O
carry	O
out	O
a	O
thorough	O
analysis	O
,	O
portable	O
oximetry	O
was	O
tested	O
both	O
in	O
the	O
hospital	O
and	O
at	O
home	O
.	O

In	O
addition	O
,	O
two	O
independent	O
populations	O
were	O
assessed	O
:	O
(	O
i	O
)	O
non	O
-	O
COPD	B-DS
subjects	O
and	O
(	O
ii	O
)	O
COPD	B-DS
patients	O
.	O

Our	O
results	O
revealed	O
that	O
no	O
significant	O
differences	O
exist	O
between	O
COPD	B-DS
and	O
non	O
-	O
COPD	B-DS
patients	O
concerning	O
the	O
capability	O
of	O
the	O
proposed	O
ANN	O
from	O
portable	O
oximetry	O
as	O
a	O
screening	O
test	O
for	O
OSAS	B-DS
.	O

In	O
our	O
aim	O
to	O
maximize	O
the	O
diagnostic	O
ability	O
of	O
portable	O
oximetry	O
,	O
we	O
proposed	O
the	O
automated	O
analysis	O
of	O
oximetric	O
recordings	O
by	O
means	O
of	O
a	O
regression	O
MLP	O
ANN	O
.	O

In	O
this	O
regard	O
,	O
ANNs	O
have	O
been	O
widely	O
applied	O
in	O
medical	O
applications	O
to	O
expedite	O
decisions	O
and	O
avoid	O
misdiagnosis	O
.	O

Particularly	O
,	O
MLP	O
is	O
probably	O
the	O
most	O
popular	O
ANN	O
and	O
it	O
has	O
demonstrated	O
to	O
be	O
very	O
useful	O
in	O
the	O
framework	O
of	O
OSAS	B-DS
management	O
[	O
23	O
,	O
24	O
,	O
26	O
,	O
47	O
,	O
48	O
].	O

The	O
study	O
by	O
Marcos	O
et	O
al	O
.	O
[	O
26	O
]	O
supports	O
the	O
usefulness	O
of	O
a	O
regression	O
-	O
based	O
MLP	O
ANN	O
for	O
estimating	O
the	O
AHI	O
using	O
supervised	O
SpO2	O
recordings	O
from	O
in	O
-	O
hospital	O
PSG	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
assessed	O
the	O
accurateness	O
and	O
reliability	O
of	O
portable	O
oximetry	O
and	O
ANNs	O
to	O
screen	O
for	O
OSAS	B-DS
at	O
COPD	B-DS
patients	O
’	O
home	O
.	O

In	O
the	O
context	O
of	O
OSAS	B-DS
detection	O
from	O
oximetry	O
,	O
simpler	O
oximetric	O
indices	O
,	O
such	O
as	O
the	O
average	O
number	O
of	O
desaturations	O
(	O
conventional	O
ODIs	O
),	O
have	O
been	O
proposed	O
[	O
31	O
,	O
49	O
,	O
50	O
].	O

Nevertheless	O
,	O
a	O
systematic	O
underestimation	O
of	O
the	O
disease	O
has	O
been	O
reported	O
and	O
the	O
performance	O
notably	O
varies	O
among	O
studies	O
[	O
4	O
,	O
51	O
,	O
52	O
].	O

In	O
the	O
present	O
research	O
,	O
we	O
proposed	O
a	O
complex	O
approach	O
based	O
on	O
ANNs	O
.	O

Our	O
experiments	O
found	O
that	O
the	O
estimated	O
AHI	O
from	O
the	O
MLP	O
ANN	O
significantly	O
outperformed	O
conventional	O
ODIs	O
in	O
terms	O
of	O
agreement	O
with	O
actual	O
AHI	O
from	O
PSG	O
both	O
in	O
the	O
hospital	O
and	O
at	O
home	O
.	O

Furthermore	O
,	O
the	O
ANN	O
reached	O
similar	O
diagnostic	O
performance	O
in	O
non	O
-	O
COPD	B-DS
and	O
COPD	B-DS
groups	O
in	O
both	O
settings	O
(	O
87	O
.	O
3	O
%	O
vs	O
.	O

86	O
.	O
8	O
%	O
Acc	O
for	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
and	O
92	O
.	O
7	O
%	O
vs	O
.	O

91	O
.	O
2	O
%	O
Acc	O
for	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
in	O
the	O
hospital	O
;	O
78	O
.	O
2	O
%	O
vs	O
.	O

75	O
.	O
0	O
%	O
Acc	O
for	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
and	O
76	O
.	O
4	O
%	O
vs	O
.	O

77	O
.	O
9	O
%	O
Acc	O
for	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
at	O
home	O
),	O
notably	O
more	O
consistent	O
than	O
conventional	O
ODI3	O
(	O
93	O
.	O
6	O
%	O
vs	O
.	O

88	O
.	O
2	O
%	O
Acc	O
for	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
and	O
86	O
.	O
4	O
%	O
vs	O
.	O

92	O
.	O
7	O
%	O
Acc	O
for	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
in	O
the	O
hospital	O
;	O
68	O
.	O
2	O
%	O
vs	O
.	O

75	O
.	O
0	O
%	O
Acc	O
for	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
and	O
67	O
.	O
3	O
%	O
vs	O
.	O

76	O
.	O
5	O
%	O
Acc	O
for	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
at	O
home	O
)	O
and	O
ODI4	O
(	O
77	O
.	O
3	O
%	O
vs	O
.	O

79	O
.	O
4	O
%	O
Acc	O
for	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
and	O
66	O
.	O
4	O
%	O
vs	O
.	O

73	O
.	O
5	O
%	O
Acc	O
for	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
in	O
the	O
hospital	O
;	O
60	O
.	O
0	O
%	O
vs	O
.	O

58	O
.	O
8	O
%	O
Acc	O
for	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
and	O
55	O
.	O
5	O
%	O
vs	O
.	O

61	O
.	O
8	O
%	O
Acc	O
for	O
AHI	O
≥	O
30	O
events	O
/	O
h	O
at	O
home	O
).	O

In	O
addition	O
,	O
once	O
optimized	O
and	O
trained	O
,	O
ANNs	O
are	O
reliable	O
,	O
easy	O
-	O
to	O
-	O
use	O
,	O
and	O
computationally	O
efficient	O
tools	O
,	O
which	O
are	O
major	O
features	O
in	O
order	O
to	O
speed	O
up	O
decision	O
-	O
making	O
.	O

Pertinent	O
features	O
derived	O
from	O
each	O
overnight	O
oximetric	O
profile	O
fed	O
the	O
neural	O
network	O
.	O

Previous	O
studies	O
showed	O
that	O
these	O
variables	O
have	O
high	O
discriminant	O
ability	O
between	O
OSAS	B-DS
-	O
negative	O
and	O
OSAS	B-DS
-	O
positive	O
patients	O
in	O
the	O
context	O
of	O
binary	O
classification	O
from	O
supervised	O
oximetry	O
[	O
32	O
–	O
34	O
].	O

In	O
the	O
present	O
study	O
,	O
we	O
assessed	O
the	O
capability	O
of	O
these	O
features	O
to	O
predict	O
the	O
AHI	O
from	O
portable	O
oximetry	O
.	O

The	O
proposed	O
FCBF	O
technique	O
for	O
variable	O
selection	O
automatically	O
identified	O
the	O
features	O
most	O
representative	O
of	O
the	O
actual	O
AHI	O
from	O
PSG	O
(	O
higher	O
symmetrical	O
uncertainty	O
)	O
as	O
well	O
as	O
the	O
less	O
redundant	O
(	O
lower	O
symmetrical	O
uncertainty	O
between	O
each	O
pair	O
of	O
variables	O
).	O

It	O
is	O
remarkable	O
that	O
M1t	O
,	O
M3t	O
,	O
M4t	O
,	O
PR	O
,	O
SampEn	O
,	O
CTM	O
,	O
and	O
LZC	O
were	O
all	O
included	O
in	O
the	O
optimum	O
feature	O
subset	O
both	O
in	O
the	O
hospital	O
and	O
at	O
home	O
,	O
which	O
evidences	O
the	O
relevancy	O
of	O
these	O
features	O
in	O
the	O
regression	O
-	O
based	O
ANN	O
for	O
AHI	O
estimation	O
.	O

They	O
gather	O
complementary	O
information	O
from	O
the	O
oximetry	O
signal	O
(	O
time	O
:	O
M1t	O
,	O
M3t	O
,	O
M4t	O
;	O
frequency	O
:	O
PR	O
;	O
and	O
nonlinear	O
:	O
SampEn	O
,	O
CTM	O
,	O
and	O
LZC	O
)	O
in	O
order	O
to	O
account	O
for	O
all	O
the	O
changes	O
linked	O
with	O
apneic	O
events	O
which	O
are	O
commonly	O
quantified	O
by	O
means	O
of	O
the	O
AHI	O
.	O

In	O
regard	O
to	O
the	O
agreement	O
between	O
estimated	O
and	O
actual	O
AHI	O
,	O
a	O
small	O
similar	O
overestimation	O
can	O
be	O
seen	O
for	O
the	O
groups	O
under	O
study	O
both	O
in	O
the	O
hospital	O
(	O
1	O
.	O
30	O
non	O
-	O
COPD	B-DS
vs	O
.	O

1	O
.	O
60	O
COPD	B-DS
)	O
and	O
at	O
home	O
(	O
0	O
.	O
61	O
non	O
-	O
COPD	B-DS
vs	O
.	O

0	O
.	O
73	O
COPD	B-DS
).	O

Nevertheless	O
,	O
the	O
diagnostic	O
performance	O
did	O
not	O
agree	O
with	O
this	O
slight	O
overall	O
overestimation	O
,	O
as	O
can	O
be	O
derived	O
from	O
Tables	O
5	O
–	O
8	O
.	O

In	O
both	O
settings	O
,	O
higher	O
sensitivity	O
than	O
specificity	O
was	O
obtained	O
for	O
the	O
groups	O
under	O
study	O
,	O
especially	O
for	O
the	O
lower	O
cutoff	O
(	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
),	O
which	O
suggests	O
a	O
systemic	O
misclassification	O
into	O
a	O
higher	O
severity	O
group	O
.	O

The	O
Bland	O
-	O
Altman	O
plots	O
in	O
Fig	O
3A	O
and	O
3B	O
show	O
different	O
trends	O
for	O
low	O
and	O
high	O
AHI	O
values	O
whatever	O
the	O
group	O
or	O
the	O
setting	O
under	O
analysis	O
.	O

Significant	O
overestimation	O
was	O
obtained	O
for	O
AHI	O
under	O
15	O
events	O
/	O
h	O
,	O
which	O
explains	O
the	O
misclassification	O
towards	O
higher	O
severity	O
classes	O
.	O

Conversely	O
,	O
an	O
important	O
underestimation	O
is	O
observed	O
for	O
higher	O
AHI	O
values	O
,	O
which	O
compensates	O
for	O
the	O
initial	O
trend	O
leading	O
to	O
a	O
slight	O
average	O
overestimation	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
this	O
behavior	O
can	O
be	O
observed	O
both	O
in	O
the	O
hospital	O
and	O
at	O
home	O
regardless	O
of	O
suffering	O
from	O
COPD	B-DS
,	O
which	O
agrees	O
with	O
our	O
initial	O
hypothesis	O
.	O

In	O
our	O
aim	O
to	O
gain	O
insight	O
into	O
the	O
usefulness	O
of	O
at	O
-	O
home	O
portable	O
oximetry	O
for	O
OSAS	B-DS
screening	O
in	O
COPD	B-DS
,	O
a	O
thoroughly	O
analysis	O
of	O
misclassified	O
COPD	B-DS
patients	O
in	O
the	O
unsupervised	O
setting	O
was	O
accomplished	O
.	O

Traditionally	O
,	O
it	O
has	O
been	O
suggested	O
that	O
profound	O
nocturnal	O
desaturations	O
characteristic	O
of	O
COPD	B-DS
could	O
lead	O
to	O
increased	O
misdiagnosis	O
in	O
oximetry	O
-	O
based	O
screening	O
tests	O
for	O
OSAS	B-DS
.	O

Nevertheless	O
,	O
our	O
findings	O
revealed	O
no	O
influence	O
on	O
the	O
diagnostic	O
capability	O
of	O
oximetry	O
linked	O
with	O
transient	O
worsening	O
due	O
to	O
COPD	B-DS
.	O

Furthermore	O
,	O
no	O
differences	O
related	O
to	O
the	O
severity	O
of	O
the	O
pulmonary	B-DS
disease	I-DS
were	O
found	O
among	O
misclassified	O
patients	O
within	O
the	O
COPD	B-DS
group	O
at	O
home	O
.	O

Regarding	O
mild	O
COPD	B-DS
(	O
GOLD	O
1	O
),	O
four	O
patients	O
showing	O
mild	O
OSAS	B-DS
were	O
misclassified	O
as	O
severe	O
using	O
AHIOX	O
-	O
HOME	O
.	O

Two	O
patients	O
showed	O
BMI	O
>	O
29	O
kg	O
/	O
m2	O
and	O
OSAS	B-DS
was	O
also	O
overestimated	O
using	O
in	O
-	O
laboratory	O
portable	O
oximetry	O
.	O

Analyzing	O
the	O
remaining	O
two	O
patients	O
,	O
both	O
were	O
hypertensive	O
and	O
one	O
had	O
a	O
BMI	O
of	O
50	O
.	O
5	O
kg	O
/	O
m2	O
.	O

In	O
regard	O
to	O
moderate	O
COPD	B-DS
patients	O
(	O
GOLD	O
2	O
),	O
just	O
one	O
non	O
-	O
OSAS	B-DS
subject	O
(	O
borderline	O
with	O
AHIPSG	O
=	O
4	O
.	O
2	O
events	O
/	O
h	O
,	O
obese	O
,	O
and	O
hypertensive	O
)	O
was	O
misclassified	O
as	O
mild	O
OSAS	B-DS
both	O
at	O
home	O
and	O
in	O
the	O
hospital	O
.	O

In	O
addition	O
,	O
six	O
OSAS	B-DS
patients	O
were	O
misclassified	O
at	O
home	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
all	O
cases	O
showed	O
significantly	O
decreased	O
(	O
5	O
patients	O
)	O
or	O
increased	O
(	O
1	O
patient	O
)	O
number	O
of	O
desaturations	O
in	O
the	O
unattended	O
setting	O
compared	O
to	O
in	O
-	O
hospital	O
recordings	O
,	O
which	O
could	O
be	O
due	O
to	O
the	O
well	O
-	O
known	O
night	O
-	O
to	O
-	O
night	O
variability	O
of	O
OSAS	B-DS
.	O

Regarding	O
severe	O
COPD	B-DS
(	O
GOLD	O
3	O
),	O
four	O
OSAS	B-DS
patients	O
were	O
incorrectly	O
classified	O
into	O
a	O
category	O
of	O
higher	O
severity	O
(	O
3	O
from	O
mild	O
to	O
moderate	O
and	O
1	O
from	O
moderate	O
to	O
severe	O
).	O

Two	O
mild	O
OSAS	B-DS
patients	O
showed	O
poor	O
sleep	O
efficiency	O
in	O
the	O
hospital	O
(<	O
55	O
%)	O
and	O
little	O
time	O
in	O
REM	O
sleep	O
,	O
which	O
could	O
hide	O
the	O
actual	O
severity	O
of	O
the	O
disease	O
.	O

The	O
moderate	O
OSAS	B-DS
patient	O
showed	O
overweight	O
(	O
BMI	O
=	O
29	O
.	O
4	O
kg	O
/	O
m2	O
).	O

On	O
the	O
other	O
hand	O
,	O
two	O
severe	O
COPD	B-DS
subjects	O
were	O
wrongly	O
classified	O
at	O
home	O
into	O
an	O
OSAS	B-DS
category	O
of	O
lower	O
severity	O
.	O

Both	O
patients	O
showed	O
significant	O
contribution	O
of	O
positional	O
apneas	O
during	O
PSG	O
and	O
they	O
presented	O
markedly	O
low	O
number	O
of	O
desaturations	O
at	O
home	O
due	O
to	O
night	O
-	O
to	O
-	O
night	O
variability	O
.	O

During	O
the	O
last	O
years	O
,	O
researchers	O
have	O
made	O
a	O
great	O
effort	O
on	O
the	O
development	O
of	O
efficient	O
screening	O
tools	O
for	O
OSAS	B-DS
based	O
on	O
portable	O
monitoring	O
in	O
order	O
to	O
expedite	O
diagnosis	O
.	O

Nevertheless	O
,	O
the	O
validation	O
of	O
almost	O
all	O
simplified	O
screening	O
tests	O
excluded	O
patients	O
with	O
significant	O
comorbidities	O
,	O
such	O
as	O
cardiovascular	O
or	O
pulmonary	B-DS
diseases	I-DS
.	O

Therefore	O
,	O
data	O
on	O
the	O
accuracy	O
of	O
abbreviated	O
methods	O
in	O
COPD	B-DS
patients	O
are	O
very	O
limited	O
[	O
13	O
,	O
16	O
,	O
17	O
].	O

In	O
fact	O
,	O
the	O
AASM	O
does	O
not	O
recommend	O
its	O
use	O
on	O
such	O
populations	O
due	O
to	O
the	O
lack	O
of	O
appropriate	O
evidences	O
supporting	O
their	O
accuracy	O
[	O
11	O
].	O
Table	O
9	O
shows	O
the	O
results	O
reported	O
in	O
the	O
scarce	O
studies	O
where	O
portable	O
monitors	O
are	O
assessed	O
for	O
OSAS	B-DS
screening	O
in	O
COPD	B-DS
patients	O
.	O

In	O
the	O
work	O
by	O
Pépin	O
et	O
al	O
.	O
[	O
20	O
],	O
the	O
delta	O
index	O
was	O
proposed	O
to	O
characterize	O
OSAS	B-DS
from	O
portable	O
oximetric	O
recordings	O
acquired	O
in	O
the	O
hospital	O
.	O

The	O
authors	O
obtained	O
promising	O
results	O
though	O
a	O
small	O
population	O
composed	O
of	O
only	O
8	O
COPD	B-DS
patients	O
was	O
analyzed	O
.	O

Evidences	O
on	O
the	O
effectiveness	O
of	O
portable	O
oximetry	O
monitoring	O
for	O
OSAS	B-DS
detection	O
in	O
patients	O
with	O
COPD	B-DS
in	O
the	O
state	O
-	O
on	O
-	O
the	O
-	O
art	O
and	O
in	O
the	O
present	O
study	O
.	O

Author	O

Population	O

Method	O
and	O
setting	O

Goal	O

Se	O
(%)	O

Sp	O
(%)	O

ICC	O

Pépin	O
et	O
al	O
.	O
(	O
1991	O
)	O
[	O
20	O
]	O

26	O
patients	O
15	O
OSAS8	O
COPD3	O
Restrictive	O

Method	O
:	O
Delta	O
indexSetting	O
:	O
In	O
-	O
hospital	O
portable	O
oximetry	O

OSAS	B-DS
detection	O
in	O
:	O
Whole	O
populationPatients	O
showing	O
basal	O
SpO2	O
<	O
93	O
%	O
COPD	B-DS
patients	O

75100100	O

8683100	O

---	O

Oliveira	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
21	O
]	O

26	O
COPD	B-DS
patients	O
showing	O
symptoms	O
of	O
suffering	O
from	O
OSAS	B-DS

Method	O
:	O
Manual	O
AHISetting	O
.	O

SpO2	O
from	O
RP	O
in	O
-	O
lab	O
and	O
at	O
home	O

Agreement	O
:	O
PSG	O
vs	O
.	O

RPLABPSG	O
vs	O
.	O

RPHOMERPLAB	O
vs	O
.	O

RPHOME	O

---	O

---	O

0	O
.	O
610	O
.	O
470	O
.	O
47	O

Scott	O
et	O
al	O
.	O
(	O
2014	O
)	O
[	O
22	O
]	O

59	O
COPD	B-DS
(	O
GOLD	O
3	O
–	O
4	O
)	O

Method	O
:	O
Visual	O
and	O
automated	O
analysesSetting	O
:	O
In	O
-	O
hospital	O
portable	O
oximetry	O

OSAS	B-DS
detection	O
(	O
AHI	O
≥	O
15	O
)	O
Visual	O
inspectionAutomated	O
ODI4	O

5960	O

6063	O

--	O

Present	O
study	O
(	O
2016	O
)	O

371	O
patients	O
showing	O
symptoms	O
of	O
suffering	O
from	O
OSAS	B-DS
193	O
training178	O
test	O
(	O
110	O
non	O
-	O
COPD	B-DS
and	O
68	O
COPD	B-DS
)	O

Method	O
:	O
Automated	O
analyses	O
by	O
MLP	O
ANNSetting	O
:	O
Portable	O
oximetry	O
in	O
-	O
lab	O
and	O
at	O
home	O

OSAS	B-DS
detection	O
in	O
the	O
hospital	O
(	O
AHI	O
≥	O
15	O
):	O
non	O
-	O
COPDCOPDOSAS	O
detection	O
at	O
home	O
(	O
AHI	O
≥	O
15	O
):	O
non	O
-	O
COPDCOPDAgreement	O
PSG	O
versus	O
MLPOX	O
-	O
LAB	O
in	O
the	O
hospital	O
non	O
-	O
COPDCOPDAgreement	O
PSG	O
versus	O
MLPOX	O
-	O
HOME	O
at	O
home	O
non	O
-	O
COPDCOPD	O

97	O
.	O
596	O
.	O
2	O
97	O
.	O
586	O
.	O
5	O
--	O
--	O

58	O
.	O
656	O
.	O
3	O
24	O
.	O
137	O
.	O
5	O
--	O
--	O

--	O
--	O
0	O
.	O
940	O
.	O
94	O
0	O
.	O
730	O
.	O
79	O

OSAS	B-DS
:	O
obstructive	B-DS
sleep	I-DS
apnea	I-DS
syndrome	I-DS
;	O
COPD	B-DS
:	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
;	O
GOLD	O
:	O
Global	O
Initiative	O
for	O
Chronic	B-DS
Obstructive	I-DS
Lung	I-DS
Disease	I-DS
;	O
AHI	O
:	O
apnea	O
-	O
hypopnea	O
index	O
;	O
SpO2	O
:	O
blood	O
oxygen	O
saturation	O
;	O
RP	O
:	O
respiratory	O
polygraphy	O
;	O
PSG	O
:	O
polysomnography	O
;	O
RPLAB	O
:	O
in	O
-	O
hospital	O
respiratory	O
polygraphy	O
;	O
RPHOME	O
:	O
respiratory	O
polygraphy	O
at	O
home	O
;	O
ODI4	O
:	O
oxygen	O
desaturation	O
index	O
of	O
4	O
%;	O
MLPOX	O
-	O
LAB	O
:	O
multilayer	O
perceptron	O
artificial	O
neural	O
network	O
trained	O
with	O
oximetric	O
recordings	O
from	O
portable	O
oximetry	O
in	O
the	O
hospital	O
;	O
MLPOX	O
-	O
HOME	O
:	O
multilayer	O
perceptron	O
artificial	O
neural	O
network	O
trained	O
with	O
oximetric	O
recordings	O
from	O
portable	O
oximetry	O
at	O
home	O
.	O

In	O
the	O
study	O
by	O
Oliveira	O
et	O
al	O
.	O
[	O
21	O
],	O
a	O
Type	O
3	O
portable	O
monitor	O
was	O
used	O
,	O
which	O
was	O
assessed	O
in	O
a	O
population	O
composed	O
of	O
26	O
COPD	B-DS
patients	O
.	O

The	O
authors	O
reported	O
a	O
moderate	O
ICC	O
equal	O
to	O
0	O
.	O
61	O
between	O
the	O
actual	O
AHI	O
from	O
PSG	O
and	O
manual	O
scoring	O
of	O
in	O
-	O
hospital	O
portable	O
recordings	O
,	O
whereas	O
the	O
agreement	O
decreases	O
up	O
to	O
0	O
.	O
47	O
when	O
the	O
monitoring	O
were	O
carried	O
out	O
at	O
home	O
.	O

In	O
a	O
recent	O
study	O
by	O
Scott	O
et	O
al	O
.	O
[	O
22	O
]	O
a	O
portable	O
oximeter	O
was	O
tested	O
in	O
the	O
hospital	O
to	O
determine	O
the	O
presence	O
or	O
absence	O
of	O
OSAS	B-DS
in	O
59	O
COPD	B-DS
patients	O
.	O

Using	O
a	O
cutoff	O
of	O
15	O
events	O
/	O
h	O
for	O
positive	O
OSAS	B-DS
,	O
visual	O
inspection	O
of	O
the	O
overnight	O
oximetric	O
profile	O
reached	O
59	O
%	O
Se	O
and	O
60	O
%	O
Sp	O
,	O
while	O
the	O
performance	O
increased	O
up	O
to	O
60	O
%	O
Se	O
and	O
63	O
%	O
Sp	O
using	O
the	O
automated	O
ODI4	O
.	O

In	O
the	O
present	O
research	O
,	O
additional	O
knowledge	O
is	O
provided	O
on	O
the	O
usefulness	O
of	O
automated	O
processing	O
of	O
portable	O
oximetry	O
as	O
a	O
single	O
tool	O
for	O
screening	O
for	O
OSAS	B-DS
in	O
COPD	B-DS
patients	O
.	O

One	O
of	O
the	O
main	O
novelties	O
of	O
our	O
study	O
is	O
that	O
the	O
impact	O
of	O
suffering	O
from	O
COPD	B-DS
on	O
the	O
capability	O
of	O
portable	O
oximetry	O
was	O
assessed	O
by	O
the	O
analysis	O
of	O
two	O
populations	O
:	O
non	O
-	O
COPD	B-DS
and	O
COPD	B-DS
independent	O
test	O
datasets	O
.	O

In	O
addition	O
,	O
the	O
proposed	O
methodology	O
based	O
on	O
automated	O
pattern	O
recognition	O
using	O
ANNs	O
was	O
validated	O
both	O
in	O
the	O
hospital	O
and	O
at	O
home	O
.	O

Regarding	O
portable	O
monitoring	O
in	O
a	O
supervised	O
setting	O
,	O
our	O
automated	O
approach	O
improved	O
the	O
performance	O
reached	O
by	O
Scott	O
et	O
al	O
.	O
(	O
60	O
%	O
Se	O
–	O
63	O
%	O
Sp	O
vs	O
.	O
96	O
.	O
2	O
%	O
Se	O
–	O
56	O
.	O
3	O
%	O
Sp	O
,	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
)	O
[	O
22	O
].	O

On	O
the	O
other	O
hand	O
,	O
our	O
sensitivity	O
–	O
specificity	O
pair	O
showed	O
higher	O
imbalance	O
.	O

In	O
the	O
unattended	O
setting	O
,	O
the	O
agreement	O
with	O
the	O
AHI	O
from	O
PSG	O
reported	O
by	O
Oliveira	O
et	O
al	O
.	O
[	O
21	O
]	O
was	O
also	O
notably	O
enhanced	O
(	O
0	O
.	O
47	O
ICC	O
vs	O
.	O
0	O
.	O
79	O
ICC	O
).	O

Essential	O
differences	O
between	O
the	O
present	O
research	O
and	O
previous	O
studies	O
account	O
for	O
the	O
dissimilarities	O
in	O
the	O
diagnostic	O
capability	O
of	O
oximetry	O
.	O

Firstly	O
,	O
datasets	O
of	O
different	O
size	O
and	O
severity	O
were	O
studied	O
.	O

In	O
this	O
regard	O
,	O
it	O
is	O
important	O
to	O
highlight	O
that	O
our	O
sample	O
size	O
is	O
larger	O
than	O
populations	O
analyzed	O
in	O
previous	O
studies	O
and	O
accounts	O
for	O
a	O
wide	O
range	O
of	O
severities	O
in	O
both	O
OSAS	B-DS
and	O
COPD	B-DS
.	O

Secondly	O
,	O
there	O
are	O
major	O
methodological	O
differences	O
among	O
studies	O
.	O

Previous	O
researchers	O
characterized	O
the	O
portable	O
recording	O
by	O
means	O
of	O
conventional	O
indices	O
,	O
such	O
as	O
the	O
delta	O
index	O
[	O
20	O
]	O
or	O
ODI4	O
[	O
22	O
],	O
or	O
proposed	O
visual	O
inspection	O
of	O
the	O
overnight	O
oximetric	O
profile	O
[	O
22	O
]	O
or	O
manual	O
scoring	O
of	O
respiratory	O
events	O
[	O
21	O
].	O

On	O
the	O
other	O
hand	O
,	O
our	O
proposal	O
is	O
based	O
on	O
advanced	O
signal	O
processing	O
techniques	O
aimed	O
at	O
deriving	O
as	O
much	O
information	O
as	O
possible	O
from	O
oximetry	O
in	O
order	O
to	O
maximize	O
its	O
diagnostic	O
ability	O
.	O

In	O
addition	O
,	O
the	O
most	O
relevant	O
and	O
complementary	O
features	O
were	O
identified	O
and	O
high	O
-	O
performance	O
pattern	O
recognition	O
techniques	O
were	O
used	O
to	O
optimally	O
manage	O
all	O
these	O
data	O
.	O

Some	O
limitations	O
of	O
the	O
study	O
should	O
be	O
discussed	O
.	O

We	O
analyzed	O
a	O
large	O
population	O
of	O
patients	O
showing	O
clinical	O
suspicion	O
of	O
OSAS	B-DS
.	O

Particularly	O
,	O
the	O
group	O
composed	O
of	O
patients	O
with	O
concomitant	O
COPD	B-DS
was	O
larger	O
than	O
in	O
previous	O
similar	O
studies	O
aimed	O
at	O
assessing	O
portable	O
oximetry	O
in	O
the	O
presence	O
of	O
comorbidities	O
found	O
in	O
the	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
.	O

Nevertheless	O
,	O
the	O
number	O
of	O
patients	O
with	O
very	O
severe	O
COPD	B-DS
(	O
GOLD	O
4	O
)	O
could	O
be	O
larger	O
in	O
order	O
to	O
generalize	O
our	O
results	O
.	O

Regarding	O
the	O
composition	O
of	O
the	O
population	O
under	O
study	O
,	O
the	O
great	O
imbalance	O
between	O
the	O
number	O
of	O
non	O
-	O
OSAS	B-DS
and	O
OSAS	B-DS
patients	O
is	O
an	O
additional	O
drawback	O
that	O
merits	O
some	O
discussion	O
.	O

Sleep	B-DS
apnea	I-DS
patients	O
were	O
predominant	O
,	O
particularly	O
severe	O
OSAS	B-DS
(	O
56	O
.	O
0	O
%	O
of	O
patients	O
in	O
the	O
training	O
set	O
,	O
57	O
.	O
3	O
%	O
in	O
the	O
non	O
-	O
COPD	B-DS
group	O
,	O
and	O
57	O
.	O
4	O
%	O
in	O
the	O
COPD	B-DS
group	O
).	O

This	O
agrees	O
with	O
the	O
prevalence	O
of	O
the	O
disease	O
reported	O
in	O
similar	O
studies	O
[	O
53	O
].	O

However	O
,	O
this	O
imbalance	O
could	O
influence	O
our	O
results	O
.	O

Although	O
we	O
used	O
a	O
regression	O
-	O
based	O
approach	O
and	O
small	O
bias	O
was	O
obtained	O
in	O
the	O
estimation	O
of	O
the	O
AHI	O
from	O
portable	O
oximetry	O
,	O
unbalanced	O
sensitivity	O
-	O
specificity	O
pairs	O
(	O
sensitivity	O
notably	O
higher	O
than	O
specificity	O
)	O
were	O
obtained	O
when	O
using	O
a	O
fixed	O
diagnostic	O
threshold	O
,	O
particularly	O
for	O
the	O
cutoff	O
AHI	O
≥	O
15	O
events	O
/	O
h	O
,	O
where	O
the	O
imbalance	O
is	O
more	O
significant	O
.	O

While	O
the	O
proposed	O
ANNs	O
could	O
be	O
optimized	O
in	O
future	O
studies	O
using	O
a	O
more	O
balanced	O
population	O
,	O
our	O
models	O
provide	O
interesting	O
insight	O
into	O
the	O
usefulness	O
of	O
portable	O
monitoring	O
for	O
OSAS	B-DS
detection	O
in	O
COPD	B-DS
patients	O
,	O
i	O
.	O
e	O
.,	O
oximetry	O
could	O
be	O
an	O
efficient	O
tool	O
as	O
a	O
simplified	O
screening	O
test	O
for	O
OSAS	B-DS
regardless	O
of	O
suffering	O
from	O
COPD	B-DS
.	O

An	O
additional	O
limitation	O
is	O
linked	O
with	O
conducting	O
the	O
unsupervised	O
oximetry	O
at	O
home	O
and	O
the	O
reference	O
PSG	O
in	O
different	O
nights	O
.	O

The	O
night	O
-	O
to	O
-	O
night	O
variability	O
of	O
OSAS	B-DS
is	O
widely	O
known	O
,	O
which	O
could	O
indirectly	O
increase	O
the	O
differences	O
between	O
the	O
actual	O
AHI	O
from	O
PSG	O
and	O
the	O
AHI	O
estimated	O
using	O
portable	O
oximetry	O
at	O
home	O
in	O
a	O
different	O
night	O
.	O

Clearly	O
,	O
the	O
agreement	O
between	O
studies	O
conducted	O
simultaneously	O
(	O
PSG	O
and	O
in	O
-	O
lab	O
oximetry	O
)	O
is	O
expected	O
to	O
be	O
higher	O
than	O
the	O
agreement	O
between	O
measures	O
derived	O
from	O
studies	O
performed	O
separately	O
(	O
PSG	O
and	O
at	O
-	O
home	O
oximetry	O
).	O

Therefore	O
,	O
the	O
decrease	O
in	O
the	O
agreement	O
between	O
the	O
actual	O
AHI	O
and	O
the	O
estimated	O
AHI	O
from	O
unattended	O
oximetry	O
in	O
the	O
home	O
setting	O
,	O
as	O
well	O
as	O
the	O
decrease	O
in	O
the	O
diagnostic	O
performance	O
,	O
could	O
be	O
mostly	O
due	O
to	O
this	O
issue	O
.	O

Nonetheless	O
,	O
both	O
the	O
non	O
-	O
COPD	B-DS
and	O
the	O
COPD	B-DS
groups	O
showed	O
similar	O
behavior	O
and	O
no	O
significant	O
differences	O
were	O
found	O
between	O
groups	O
,	O
which	O
confirm	O
our	O
initial	O
hypothesis	O
.	O

Conclusions	O

A	O
simplified	O
screening	O
test	O
for	O
OSAS	B-DS
based	O
on	O
automated	O
analysis	O
of	O
portable	O
oximetry	O
by	O
means	O
of	O
a	O
regression	O
ANN	O
exhibited	O
no	O
significant	O
differences	O
between	O
non	O
-	O
COPD	B-DS
and	O
COPD	B-DS
patients	O
in	O
terms	O
of	O
diagnostic	O
performance	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
the	O
estimated	O
AHI	O
from	O
oximetry	O
and	O
its	O
agreement	O
with	O
the	O
actual	O
AHI	O
from	O
PSG	O
were	O
similar	O
regardless	O
of	O
the	O
presence	O
of	O
COPD	B-DS
both	O
in	O
the	O
laboratory	O
and	O
at	O
home	O
.	O

Furthermore	O
,	O
in	O
the	O
home	O
setting	O
,	O
the	O
proposed	O
regression	O
ANN	O
performed	O
similar	O
in	O
patients	O
with	O
such	O
comorbid	O
condition	O
regardless	O
of	O
the	O
severity	O
of	O
COPD	B-DS
,	O
particularly	O
in	O
stages	O
GOLD	O
1	O
to	O
3	O
.	O

Our	O
results	O
suggest	O
that	O
automated	O
analysis	O
of	O
unsupervised	O
portable	O
oximetry	O
at	O
home	O
may	O
be	O
recommended	O
as	O
an	O
efficient	O
tool	O
for	O
moderate	O
-	O
to	O
-	O
severe	O
OSAS	B-DS
diagnosis	O
also	O
in	O
the	O
presence	O
of	O
COPD	B-DS
.	O

Supporting	O
information	O

Actual	O
AHI	O
from	O
PSG	O
,	O
ODI3	O
,	O
ODI4	O
,	O
and	O
estimated	O
AHI	O
from	O
the	O
proposed	O
oximetry	O
-	O
based	O
MLP	O
ANN	O
both	O
in	O
the	O
hospital	O
and	O
at	O
home	O
of	O
each	O
subject	O
in	O
the	O
non	O
-	O
COPD	B-DS
test	O
dataset	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Actual	O
AHI	O
from	O
PSG	O
,	O
ODI3	O
,	O
ODI4	O
,	O
and	O
estimated	O
AHI	O
from	O
the	O
proposed	O
oximetry	O
-	O
based	O
MLP	O
ANN	O
both	O
in	O
the	O
hospital	O
and	O
at	O
home	O
of	O
each	O
subject	O
in	O
the	O
COPD	B-DS
test	O
dataset	O
.	O

(	O
XLSX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

